

Supplementary Material

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease

Publication list

Refereed Journal Articles Only (no abstracts, conference proceedings, etc.)

2001

- 01.01 Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PR, Masters CL, Currie J. Memory decline in healthy older people: Implications for identifying mild cognitive impairment. **Neurology** 2001; 56: 1533-1538.

2004

- 04.01 Maruff P, Collie A, Darby D, Weaver-Cargin J, Masters C, Currie J. Subtle memory decline over 12 months in mild cognitive impairment. **Dement Geriatr Cogn Disord** 2004; 18: 342-348.

2005

- 05.01 Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. **J Clin Neurosci** 2005; 12: 221-230.

2006

- 06.01 Weaver Cargin J, Maruff P, Collie A, Masters C. Mild memory impairment in healthy older adults is distinct from normal aging. **Brain Cogn** 2006; 60: 146-155.
- 06.02 Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics. **J Neurochem** 2006; 97: 1700-1725.
- 06.03 Villemagne VL, Ng S, Cappai R, Barnham KJ, Fodero-Tavoletti MT, Rowe CC, Masters CL. *La LungaAttesa*: Towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. **Neuroradiol J** 2006; 19: 453-474.
- 06.04 Collie A, Maruff P, Darby DG, Masters C, Currie J. The Melbourne Aging Study. In: *Mild Cognitive Impairment: International Perspectives*. Edited by Tuokko HA, Hultsch DF. New York: Taylor & Francis; 2006: 93-113.

2007

- 07.01 Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging β -amyloid burden in aging and dementia. **Neurology** 2007; 68: 1718-1725. [See also Rowe CC, Villemagne VL, Masters CL. Correspondence: In reply to Linzasoro G. **Neurology** 2008; 70: 1650].
- 07.02 Weaver Cargin J, Maruff P, Collie A, Shafiq-Antonacci R, Masters C. Decline in verbal memory in non-demented older adults. **J Clin Exp Neuropsychol** 2007; 29: 706-718.
- 07.03 Ng S, Villemagne VL, Berlangieri S, Lee S-T, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O'Keefe G, Masters CL, Rowe CC. Visual assessment versus quantitative assessment of ^{11}C -PiB PET and ^{18}F -FDG PET for detection of Alzheimer's Disease. **J Nucl Med** 2007; 48: 547-552.
- 07.04 Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11-labeled Pittsburgh Compound B. **Arch Neurol** 2007; 64: 1140-1144.
- 07.05 Khalil Z, LoGuidice D, Khodr B, Maruff P, Masters C. Impaired peripheral endothelial microvascular responsiveness in Alzheimer's disease. **J Alzheimers Dis** 2007; 11: 25-32.
- 07.06 Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC. β -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. **Brain** 2007; 130: 2837-2844.
- 07.07 Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortés M, Culvenor JG, Li Q-X, Loughton KN, Rowe CC, Masters CL, Cappai R, Villemagne VL. *In vitro* characterization of Pittsburgh compound-B binding to Lewy bodies. **J Neurosci** 2007; 27: 10365-10371.

2008

- 08.01 Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis K, Maruff P, Currie J, Villemagne VL, Rowe C, Salvado O and Ourselin S. Appearance modelling of C11 PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. **Neuroimage** 2008; 43: 430-439

2009

- 09.01 Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoek C, Taddei K, Villemagne V, Woodward M, Ames D and the AIBL Research Group. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging:

methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. **Int Psychogeriatr** 2009; 21: 672-687.

- 09.02 Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL. Amyloid imaging in Alzheimer's disease and other dementias. **Brain Imag Behav** 2009; 3: 246-261.
- 09.03 Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li Q-X, Masters CL, Cappai R, Villemagne VL. Characterization of PiB binding to white matter in AD and other dementias. **J Nucl Med** 2009; 50: 198-204.
- 09.04 Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL. *In vitro* characterisation of BF227 binding to a-synuclein/Lewy Bodies. **Eur J Pharmacol** 2009; 617: 54-58.
- 09.05 Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, Jones G, Baxendale D, Masters CL, Rowe CC, Collins SJ. ¹¹C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. **J Neurol Neurosurg Psychiatry** 2009; 80: 998-1001.
- 09.06 Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O'Keefe GJ, Masters CL, Mori H, Rowe CC. High striatal amyloid b-peptide deposition across different autosomal Alzheimer's disease mutation types. **Arch Neurol** 2009; 66: 1537-1544.
- 09.07 Okamura N, Fodero-Tavoletti MT, Kudo Y, Rowe CC, Furumoto S, Arai H, Masters CL, Yanai K, Villemagne VL. Advances in molecular imaging for the diagnosis of dementia. **Expert Opin Med Diagn** 2009; 3: 705-716.
- 09.08 Acosta O, Bourgeat P, Frripp J, Zuluaga MA, Frripp J, Salvado O, Ourselin S. Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. **Medical Image Analysis** 2009; 13: 730-743.
- 09.09 Bates KA, Verdile G, Li Q-X, Ames D, Hudson P, Masters CL and Martins RN. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. **Mol Psychiatry** 2009; 14: 469-486

2010

- 10.01 Bourgeat P, Chételat G, Villemagne VL, Frripp J, Raniga P, Pike K, Acosta O, Szoëke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O on behalf of the AIBL Research Group. β -amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. **Neurology** 2010; 74: 121-127.
- 10.02 Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoëke C, Ames D and the AIBL Research group. Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle Study: Collaboration

with the Alzheimer's Disease Neuroimaging Initiative. **Alzheimers Dement** 2010; 6: 291-296.

- 10.03 Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, Faux NG, Masters CL, Barnham KJ. Blood borne amyloid- β dimer correlates with clinical markers of Alzheimer's disease. **J Neurosci** 2010; 30: 6315-6322.
- 10.04 Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeka C, Martins RN, O'Keefe GJ, Salvado O, Masters CL, Rowe CC and the Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and β -amyloid deposition in Alzheimer disease. **Ann Neurol** 2010; 67: 317-324. [See also editorial: Rabinovici GD and Roberson ED. Beyond diagnosis: what biomarkers are teaching us about the "biology of Alzheimer disease. **Ann Neurol** 2010; 67: 283-285.
- 10.05 Villemagne VL, Pike K, Pejoska S, Boyd A, Power M, Jones G, Masters CL, Rowe CC. ^{11}C -PiB PET A_{Bri} imaging in Worster-Drought syndrome (Familial British Dementia): A case report. **J Alzheimers Dis** 2010; 19: 423-428.
- 10.06 Lui JK, Laws SM, Li Q-X, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromei J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeka C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN for the AIBL Research Group. Plasma amyloid- β as a biomarker in Alzheimer's Disease: The AIBL Study of Aging. **J Alzheimers Dis** 2010; 20: 1233-1242.
- 10.07 Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandea L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeka C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. **Neurobiol Aging** 2010; 31: 1275-1283.
- 10.08 Chételat G, Villemagne VL, Pike KE, Baron J-C, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeka C, Martins RN, Ames D, Masters CL, Rowe CC and Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger temporal volume in elderly with high versus low beta-amyloid deposition. **Brain** 2010; 133: 3349-3358.
- 10.09 Rueda A, Acosta O, Couprie M, Bourgeat P, Fripp J, Dowson N, Romero E, Salvado O. Topology-corrected segmentation and local intensity estimates for improved partial volume classification of brain cortex in MRI. **J Neurosci Methods** 2010; 188: 305-315.
- 10.10 Bahar-Fuchs A, Moss S, Pike KE, Villemagne VL, Masters CL, Rowe C, Savage G. Olfactory deficits and Ab burden in AD, MCI and healthy ageing: a PiB PET Study. **J Alzheimers Dis** 2010; 22: 1081-1087.

2011

- 11.01 Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan R, Bourgeat P, Ackermann U, Jones G, Szoeki C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of A β and cognition in aging and Alzheimer's disease. **Ann Neurol** 2011; 69: 181-192.
- 11.02 Ellis KA, Rowe CC, Szoeki CEI, Villemagne VL, Ames D, Chételat G, Martins RN, Masters CL, Fripp J, Acosta O, Raniga P, Bourgeat PT, Salvado O. Advances in structural and molecular neuroimaging in Alzheimer's disease. **Med J Aust** (Supplement) 2011; 194: 520-23.
- 11.03 Lim NK-H, Villemagne VL, Soon CPW, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li Q-X. Investigation of matrix metalloproteinases, MMP-2 and MMP-9 in plasma reveals a decrease of MMP-2 in Alzheimer's disease. **J Alzheimers Dis** 2011 Jan 1; 26: 779-86.
- 11.04 Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, Szoeki C, Taddei K, Martins RN for the AIBL Research Group. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. **Neurol** 2011; 76: 1091-1098.
- 11.05 Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeki C, Ellis KA, and the AIBL research group. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. **Dement Geriatr Cogn Disord** 2011; 31:173-178.
- 11.06 McBride SJ, Szoeki CEI, Good NM, Ames D, Martins RN, Masters CL, Maruff PT, Rowe CC, Savage G, Ellis KA and the AIBL Research Group. A web-based normative data tool for assessing cognitive performance in healthy older Australians. **Med J Aust** (Supplement) 2011; 194: 512-14.
- 11.07 Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, Ames D, O'Keefe GJ, Salvado O, Szoeki C, Martins RN, Ames D, Masters CL, Rowe CC and the Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group. Independent contribution of temporal Ab deposition to memory decline in the predementia phase of Alzheimer's disease. **Brain** 2011; 134: 798-807.
- 11.08 Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL, Villemagne VL, Barnham KJ. Increasing the predictive accuracy of beta-amyloid blood-borne biomarkers in Alzheimer's disease. **J Alzheimers Dis** 2011; 24: 47-59.
- 11.09 Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor A, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. ¹⁸F-THK523: a novel *in vivo* tau imaging ligand for Alzheimer's disease. **Brain** 2011; 134: 1089-1100.
- 11.10 Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeki C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC. Cognition and beta-amyloid in

preclinical Alzheimer's disease: data from the AIBL study. **Neuropsychologia** 2011; 49: 2384-90.

- 11.11 Fodero-Tavoletti MT, Villemagne VL, Rowe CC, Masters CL, Barnham KJ, Cappai R. Amyloid- β : The seeds of darkness. **Int J Biochem Cell Biol** 2011; 43: 1247-51.
- 11.12 Mattsson N, Andreason U, Persson S, Arai H, Batish D, Bernardini S, Bocchio-Chiavetto L, Blankenstein RA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan A, Forlenza O, Frisoni G, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovitz AZ, Herukka S-K, Holtzman DM, Humpel C, Hyman B, Iqbal K, Jucker M, Kaeser S, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen C, Kummer M, Liu J, Lladó A, Lewczuk P, Li Q-X, Martins R, Masters CL, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine T, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen R, Prvulovic D, de Reus HPM, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski J, Tumani H, Umek R, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek M, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer's Association external quality control program for CSF biomarkers. **Alzheimers Dement** 2011; 7: 386–395.
- 11.13 Yates PA, Sirisriro R, Villemagne VL, Farquason S, Masters CL, Rowe CC and the AIBL Research Group. Cerebral microhaemorrhage and brain A β amyloid in healthy ageing and Alzheimer's disease. **Neurol** 2011; 77: 48 – 54.
- 11.14 Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, Dumont J, Richard F, Cattel D, Berr C, Ames D, Masters CL, Rowe CC, Szoeka C, Tzourio C, Dartigues JF, Buée L, Martins R, Amouyel P. Association of plasma A β peptides with blood pressure in the elderly. **PLoS One** 2011 April 15; 6.
- 11.15 Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeka C, Taddei K, Taddei T, Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, the AIBL Research Group, Bush AI. Homocysteine, vitamin B12 and folic acid levels in Alzheimer's disease, mild cognitive impairment and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. **J Alzheimers Dis** 2011; 27: 909-22.
- 11.16 Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo M, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: Recommendations of the National Institute on Aging and the Alzheimer's Association workgroup. **Alzheimers Dement** 2011; 7: 280-92.
- 11.17 Leroux H, McBride S, Gibson S. On selecting a clinical trial management system for large scale, multi-centre, multi-modal clinical research study. **Stud Health Technol Inform** 2018: 168; 89-95.

2012

- 12.01 Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins R, Masters C, Rowe C, Szoeka C, Taddei K, Ellis K and the AIBL research group. Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian, Imaging, Biomarker and Lifestyle (AIBL) study of ageing. **Int Psychogeriatr** 2012; 24: 197-204.
- 12.02 Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, Ikonomic MD, Ishii K, Jack CR, Jagust WJ, Johnson KA, Koeppe RA, Lowe VJ, Masters CL, Montine TJ, Morris JC, Nordberg A, Petersen RC, Reiman EM, Selkoe DJ, Sperling RA, Van Laere K, Weiner MW, Drzezga A. A β Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. **Eur J Nucl Med Mol Imaging** 2012; 39:209-219.
- 12.03 Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC and the AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high β -amyloid deposition. **Neurology** 2012; 78: 477-484.
- 12.04 Lim YY, Ellis K, Harrington K, Ames D, Martins R, Masters C, Rowe C, Szoeka C, Darby D, Maruff P. Use of CogState brief battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. **J Clin Exp Neuropsychol** 2012; 34: 345-58.
- 12.05 Barber B, Ames D, Ellis K, Martins R, Masters C, and Szoeka C. Lifestyle and late life cognitive health: sufficient evidence to act now? [Guest Editorial] **Int Psychogeriatr** 2012; 24: 683-688.
- 12.06 Chételat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC, and the Australian Imaging Biomarker and Lifestyle study of Ageing (AIBL) Research Group. Relationships between memory performances and β -amyloid deposition at different stages of Alzheimer's disease. **Neurodegener Dis** 2012; 10: 141-144.
- 12.07 Head R, Ames D, Masters CL, Rowe CC, Macaulay SL, and the Australian Imaging Biomarker and Lifestyle study of Ageing. The AIBL study throwing light on amyloid-beta and Alzheimer's disease. **Med J Aust** 2012; 196: 376-377.
- 12.08 Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC. Comparison of (11)C-PiB and (18)F-florbetaben for A-beta imaging in ageing and Alzheimer's disease. **Eur J Nucl Med Mol Imaging** 2012; 39: 983-9.
- 12.09 Acosta O, Fripp J, Dore V, Bourgeat P, Favreau J-M, Chételat G, Rueda A, Villemagne VL, Szoeka C, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Bonner E, Gris F, Xiao D, Raniga P, Barra V, Salvado O. Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. **J Neurosci Methods** 2012; 205: 96-109.
- 12.10 Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, O'Keefe G, Jones G, Kung HF, Pontecorvo M, Masters CL, Skovronsky DM, Rowe CC. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and

amyloid imaging. (In: Proceedings of the 10th International Conference on AD/PD 2011. Edited by Nitsch RM, Fisher A, Windisch M, Hanin I.) **Neurodegen Dis** 2012; 10: 161-165.

- 12.11 Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ. Variability in blood based amyloid beta assays: The need for consensus on pre-analytical processing. **J Alzheimers Dis** 2012; 30: 323-336.
- 12.12 Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL and the AIBL research group. Regional dynamics of amyloid-beta deposition in healthy elderly, Mild Cognitive Impairment and Alzheimer's Disease: a voxelwise PiB-PET longitudinal study. **Brain** 2012; 135: 2126-2139.
- 12.13 Lim YY, Harrington K, Ames D, Ellis KA, Lachovitzki R, Snyder PJ, Maruff P. Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. **J Clin Exp Neuropsychol** 2012; 34: 853 – 863.
- 12.14 Fodero-Travoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, Berndt M, McLean CA, Krause S, Rowe CC, Masters CL, Dyrks T, Cappai R. *In Vitro* characterisation of ¹⁸F-Florbetaben, an A β imaging radiotracer. **Nucl Med Biol** 2012; 39: 1042-1048.
- 12.15 Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeka C, Villemagne VL, Maruff P and the AIBL Research Group. Stronger effect of amyloid load than ApoE genotype on cognitive decline in healthy older adults. **Neurology** 2012; 79: 1645-1652.
- 12.16 Villemagne VL, Furumoto S, Fodero-Travoletti MT, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, Okamura N. The challenges of tau imaging. **Future Neurol** 2012, 7(4):409-421.
- 12.17 Cyarto EV, Lautenschlager NT, Desmond PM, Ames D, Szoeka C, Salvado O, Sharman MJ, Ellis KA, Phal PM, Masters CL, Rowe CC, Martins RN and Cox KL. Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. **Bio Med Central Psychiatry** 2012; 12: 167.
- 12.18 Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam C-P, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeka C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, for the Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging Biomarker and Lifestyle research group. Blood-based protein biomarkers for diagnosis of Alzheimer's disease. **Arch Neurol** 2012; 69:1318-1325 [see also In Reply: Laske C. Blood-based biomarkers in Alzheimer's disease: where are we now, where have we to go? and Laws SM, Doecke J, Martins RN. In reply: "Blood-based biomarkers in Alzheimer's disease: where are we now, where have we to go?" – Christoph Laske. **Arch Neurol**].

- 12.19 Gardener S, GuY, Rainey-Smith S, Keogh JB, Clifton PM, Mathieson SL, Taddei K, Mondal A, Ward VK, Scarmeas N, Barnes M, Ellis KA, Head R, Masters CL, Ames D, Macaulay L, Rowe CC, Szoeki C, Martins RN and The AIBL Research Group. Adherence to a Mediterranean diet and Alzheimer's disease risk in an Australian population. **Transl Psychiatry** 2012 Oct 2; 2: e164.
- 12.20 Brown BM, Peiffer JJ, Sohrabi HR, Mondal A, Gupta VB, Rainey-Smith SR, Taddei K, Burnham S, Ellis KA, Szoeki C, Masters CL, Ames D, Rowe CC, Martins RN, and the AIBL research group. Intense physical activity is associated with cognitive performance in the elderly. **Transl Psychiatry** 2012 Nov 2; 2: e191.
- 12.21 Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Villemagne VL, Rowe CC, Frapp J and the AIBL Research Group. MR-less Surface-based Amyloid estimation by subject-specific atlas selection and Bayesian fusion. **Med Image Comput Comput Assist Interv** 2012; 15: 220-227.

2013

- 13.01 Rembach A, Doecke J, Roberts B, Duce JA, Faux NG, Volitakis I, Trounson B, Fowler CJ, Pertile KK, Rumble BL, Varghese J, Ellis KA, Rowe CC, Martins RN, Ames D, Masters CL, Bush AI and the AIBL research group. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. **J Alzheimers Dis** 2013; 34: 171-182.
- 13.02 Ellis KA, Lim YY, Harrington K, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeki C, Villemagne VL, Maruff P, AIBL research group. Decline in cognitive function over 18 months in healthy older adults with high A-beta amyloid. **J Alzheimers Dis** 2013; 34: 861-871.
- 13.03 Carillo MC, Rowe CC, Szoeki C, Masters CL, Ames D, O'Meara T, Macaulay L, Milner A, Ellis K, Maruff P, Rainey-Smith SR, Martins RN, Bain LJ, Head RJ. Research and standardization in Alzheimer's trials: Reaching international consensus. **Alzheimers Dement** 2013; 9: 160-168.
- 13.04 Lim YY, Pietrzak RH, Ellis KA, Jaeger J, Harrington K, Ashwood T, Szoeki C, Martins RN, Bush AI, Masters CL, Rowe CC, Villemagne VL, Ames D, Darby D, Maruff P. Rapid decline in episodic memory in healthy older adults with high Amyloid- β . **J Alzheimers Dis** 2013; 33: 675-679.
- 13.05 Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeki C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. **Lancet Neurol** 2013; 12: 357-367 [See also comment: Schneider LS. Quantifying an amyloid β model for Alzheimer's disease. **Lancet Neurol** 2013; 12: 327-328].
- 13.06 Frost S, Kanagasam Y, Sohrabi H, Bourgeat P, Salvado O, Villemagne V, Rowe CC, Macaulay SL, Szoeki C, Ellis KA, Ames D, Masters CL, Rainey-Smith S, Martins RN,

and the AIBL research group. Retinal vascular biomarkers for early detection and monitoring of Alzheimer's Disease. **Transl Psychiatry** 2013 Feb 6;3: e233.

- 13.07 Lim YY, Ellis KA, Harrington K, Kamer A, Pietrzak RH, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeka C, Villemagne V, Ames D, Maruff P, and the AIBL research group. Cognitive consequences of high A-beta amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's Disease. **Neuropsychology** 2013; 27: 322-332.
- 13.08 Doré V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetelat G, Zhou L, Martins R, Ellis KA, Masters CL, Ames D, Salvado O and Rowe CC. Cross-sectional and longitudinal analysis of the relationship between A β deposition, cortical thickness and memory in cognitively unimpaired individuals and in Alzheimer's disease. **JAMA Neurol** 2013; 70: 903-911.
- 13.09 Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, Cselényi Z, Masters CL, Villemagne VL. Head to head comparison of ¹¹C-PiB and ¹⁸F-AZD4694 (NAV4694) for A β imaging in aging and dementia. **J Nucl Med** 2013; 54: 880-886.
- 13.10 Buckley R, Saling M, Ames D, Lautenschlager N, Macauley SL, Martins RN, Masters CL, O'Meara T, Rowe CC, Savage G, Szoeka C, Villemagne VL, Ellis KA for the Australian Imaging Biomarkers and Lifestyle Research Group. Factors affecting subjective memory complaints in the AIBL aging study: biomarker, memory, affect and age. **Int Psychogeriatr** 2013; 25: 1307-1315.
- 13.11 Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington KD, Bourgeat P, Salvado O, Darby D, Snyder PJ, Bush AI, Martins RN, Masters CL, Rowe CC, Nathan PJ, Maruff P for the AIBL Research Group. BDNF Val66Met, A β amyloid, and cognitive decline in preclinical Alzheimer's disease. **Neurobiol Aging** 2013; 34: 2457-2464.
- 13.12 Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA, Stoffler A, Szoeka C, Lachovitzki R, Martins RN, Villemagne VL, Bush A, Masters CL, Rowe CC, Ames D, Darby D, Maruff P. Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). **Archives Clin Neuropsychology** 2013; 28: 320-330.
- 13.13 Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chetelat G, Raniga P, Mulligan RS, Salvado O, Putz B, Roth K, Masters CL, Reiningner CB and Rowe CC. ¹⁸F-florbetaben A β imaging in mild cognitive impairment. **Alzheimers Res Therapy** 2013; 5: 4.
- 13.14 Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan A, Heegaard N, Hsiung G-YR, Hyman B, Iqbal K, Lachno DR, Lleó, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K; on behalf of the Alzheimer's Association QC Program Work Group. CSF biomarker variability in the Alzheimer's Association quality control program. **Alzheimers Dement** 2013; 9: 251-261.

- 13.15 Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, Taddei T, Ward VK, Rodrigues MA, Burnham S, Rainey-Smith SR, Villemagne VL, Bush A, Ellis KA, Masters CL, Ames D, Macaulay SL, Szoeka C, Rowe CC, and Martins RN, for the AIBL Research Group. Physical activity and amyloid- β plasma and brain levels: results from the Australian, Imaging, Biomarkers and Lifestyle Study of Ageing. **Molec Psych** 2013; 18: 875-881
- 13.16 Foster JK, Albrecht MA, Savage G, Lautenschlager NT, Ellis KA, Maruff P, Szoeka C, Taddei K, Martins R, Masters CL, Ames D and the AIBL Research Group. Lack of reliable evidence for a distinctive $\epsilon 4$ -related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle study. **Brain** 2013; 136: 2201-2216.
- 13.17 Burnham SC, Villemagne VL, Macaulay SL. The AIBL study: opening the presymptomatic window in Alzheimer disease. **MJA** 2013; 198:578.
- 13.18 Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM. Update on appropriate use criteria for Amyloid PET imaging: Dementia experts, mild cognitive impairment and education. **Alzheimers Dement** 2013; 9: e106-109.
- 13.19 Harrington KD, Lim YY, Ellis KA, Copolov C, Darby D, Weinborn M, Ames D, Martins RN, Savage G, Szoeka C, Rowe C, Villemagne VL, Masters CL, Maruff P. The association of A β amyloid and composite cognitive measures in healthy older adults and MCI. **Int Psychogeriatr** 2013; 25: 1667-1677.
- 13.20 Rembach A, Ryan TM, Roberts BR, Doecke JD, Wilson WJ, Watt AD, Barnham KJ and Masters CL. Progress towards a consensus biomarker for Alzheimer's disease: a review of peripheral based analytes. **Biomark Med** 2013; 7: 641-662.
- 13.21 Lim YY, Ellis KA, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeka C, Villemagne VL, Maruff P for the AIBL research group. A β amyloid, cognition and APO E genotype in healthy older adults. **Alzheimers Dement** 2013; 9: 538-545.
- 13.22 Lim YY, Ellis KA, Harrington K, Pietrzak RH, Gale J, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe C, Savage G, Szoeka C, Villemagne VL, Maruff P and the AIBL Research Group. Cognitive decline in adults with amnesic mild cognitive impairment and high A-beta amyloid: Prodromal Alzheimer's Disease. **J Alzheimers Dis** 2013; 33: 1167-1176.
- 13.23 Rembach A, Hare DJ, Lind M, Fowler CJ, Cherny RA, McLean C, Bush AI, Masters CL, Roberts BR. Decreased copper in Alzheimer's disease brain is predominantly in the soluble extractable fraction. **Int J Alzheimers Dis** 2013: 623241.
- 13.24 Ellis KA, Rainey-Smith SR, Rembach A, Macaulay SL, Villemagne VL and the AIBL research group. Enabling a multidisciplinary approach to the study of aging and Alzheimer's disease: An update from the AIBL study. **Int Rev Psychiatry** 2013; 25: 699-710.

- 13.25 Sona A, Ellis KA, Ames D. Rapid cognitive decline in Alzheimer's disease: a literature review. **Int Review Psychiatry** 2013; 25: 650-658.
- 13.26 Villemagne VL, Rowe CC. Long night's journey into the day: amyloid beta imaging in Alzheimer's disease. **J Alzheimers Dis** 2013; 33: S349-359.
- 13.27 Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK, Barnes J, Villemagne VL, Rowe CC, Fox NC, Ourselin S, Schott JM. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. **PLoS One** 2013; 8: e58816.
- 13.28 Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O'Keefe G, Pike KE, Szoek C, Salvado O, Macaulay SL, O'Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D & Villemagne VL. Predicting Alzheimer's disease with beta-amyloid imaging: Results from AIBL. **Ann Neurol** 2013; 74: 905-913.
- 13.29 Frost S, Kanagasigam Y, Sohrabi H, Bourgeat P, Villemagne V, Rowe CC, Macaulay SL, Szoek C, Ellis KA, Ames D, Masters CL, Rainey-Smith S, Martins RN; AIBL Research Group. Pupil response biomarkers for early detection and monitoring of Alzheimer's disease. **Curr Alzheimer Res** 2013; 10: 931-939.
- 13.30 Bourgeat P, Dore V, Villemagne VL, Rowe CC, Salvado O, Fripp J. MilxXplore: a web-based system to explore large imaging datasets. **J Am Med Inform Assoc** 2013; 20: 1046-1052.
- 13.31 Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. **Med Clin North Am** 2013; 97: 377-398.
- 13.32 Rowe CC, Villemagne VL. Brain amyloid imaging. **J Nucl Med Technol** 2013; 41: 11-18.
- 13.33 Maruff P, Lim YY, Darby D, Ellis KA, Pietrzak RH, Snyder PJ, Bush AI, Szoek C, Savage G, Ames D, Masters CL for the AIBL Research Group. Clinical utility of the CogState brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. **BMC Pharma and Toxicol** 2013; 1: 30.
- 13.34 Szoek CEI, Robertson JS, Rowe CC, Yates P, Campbell K, Masters CL, Ames D, Dennerstein L and Desmond P. The Women's Healthy Ageing Project: Fertile ground for investigation of healthy participants "at risk" for dementia. **Int Rev Psychiatry** 2013; 25: 726-737.
- 13.35 Ames D, Ritchie C. Prospective cohort studies in dementia. **Int Rev Psychiatry** 2013; 25: 647-649.

2014

- 14.01 Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ, Martins RN, Pertile KK, Rumble RL, Trounson B, Masters CL, The AIBL Research Group, Bush AI. An anemia of Alzheimer's disease. **Mol Psychiatry** 2014; 19: 1227-1234.
- 14.02 Rembach A. Alzheimer disease: the search for a blood-based biomarker for Alzheimer disease. **Nat Rev Neurol** 2014; 10: 618-619.
- 14.03 Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, Ames D, Masters CL, Ellis KA, Villemagne VL, Rowe CC, Fripp J, AIBL Research Group. MR-less surface-based amyloid assessment based on ¹¹C PiB PET. **PLOS One** 2014; 9: e84777.
- 14.04 Pietrzak RH, Scott JC, Neumeister A, Lim YY, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeka C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P; the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year perspective cohort study. **Br J Psychiatry** 2014; 204: 400-1.
- 14.05 Buckley RF, Saling MM, Irish M, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Macaulay SL, Martins RN, Masters CL, Rainey-Smith SR, Rembach A, Savage G, Szoeka C, Ellis KA. Personal memory function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. **J Alzheimers Dis** 2014; 40: 551 – 561.
- 14.06 Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: A review of clinical, genetic, and neuroimaging associations. **Front Neurol** 2014; 4: 205.
- 14.07 Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeka C, Martins RN, Masters CL, Villemagne VL, Rowe CC for the AIBL Research Group. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. **Brain** 2014; 137: 221-223.
- 14.08 Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li Q-X, Masters CL, Pike KE, Rowe CC, Szoeka C, Taddei K, Villemagne VL, and Martins RN for the AIBL Research Group. Associations between gonadotropins, testosterone, and β amyloid in men at risk of Alzheimer's Disease. **Mol Psych** 2014; 19: 69-75.
- 14.09 Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chètelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, dela Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M and the Subjective Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. **Alzheimers Dement** 2014; 10: 844-852.

- 14.10 Ellis K, Szoeka C, Bush A, Darby D, Graham P, Lautenschlager N, Macaulay L, Martins R, Maruff P, Masters C, McBride S, Rainey-Smith S, Rembach A, Robertson J, Rowe C, Savage G, Woodward M, Wilson W, Villemagne V, Zhang P, Ames D and the AIBL investigators. Rates of diagnostic transition and cognitive change at 18 month follow up among 1112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship study of Ageing (AIBL). **Int Psychogeriatr** 2014; 26: 543-554.
- 14.11 Moore E, Ames D, Mander AG, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis K, Bush AI, Faux NG, Martins R, Masters CL, Rowe C, Szoeka C, Watters DA, and the AIBL investigators. Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. **J Alzheimers Dis** 2014; 39:661-668.
- 14.12 Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, RS Mulligan, Birchall I, Harada R, Masters CL, Yanai K, Kudo Y, Rowe CC, Okamura N and Villemagne VL. Assessing THK 523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer disease tauopathies. **Alzheimers Res Ther** 2014; 6: 11.
- 14.13 Yates PA, Desmond PM, Phal PM, Steward C, Szoeka C, Salvado O, Ellis KA, Martins RN, Masters CL, Ames D, Villemagne VL, Rowe CC for the AIBL research group. Incidence of cerebral microbleeds in preclinical Alzheimer disease. **Neurology** 2014; 82: 1266-1273.
- 14.14 Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington K, Bourgeat P, Salvado O, Bush AI, Martins RN, Masters CL, Rowe CC, Maruff P for the AIBL Research Group. Effect of *BDNF* Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: A preliminary study. **PLoS One** 2014; 9: e86498. Doi:10.1371/journal.pone.0086498.
- 14.15 Lim YY, Maruff P, Pietrzak RH, Ellis KA, Darby D, Ames D, Harrington K, Martins RN, Masters CL, Szoeka C, Savage G, Villemagne VL, Rowe CC for the AIBL Research Group. A β and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. **Alzheimers Dement** 2014; 10: 743-751.
- 14.16 Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD. Plasma amyloid- β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. **J Alzheimers Dis** 2014; 40: 95-104.
- 14.17 Brodaty H, Mothakunnel A, De Vel-Palumbo M, Ames D, Ellis K, Reppermund S, Kochan NA, Savage G, Troller J, Crawford J, Sachdev PS. Influence of population versus convenience sampling on sample characteristics in studies of cognitive ageing. **Ann Epidemiol** 2014; 24: 63-71.
- 14.18 Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li Q-X, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeka C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martin RN, Bush AI, Masters CL and the AIBL research

group. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. **Alzheimers Dement** 2014; 10: 53-61.

- 14.19 Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke J, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rowe C, Salvado O, Macaulay L, Masters CL, Villemagne V and the AIBL Research Group. A blood based predictor for neocortical Amyloid burden in Alzheimer's disease: Results from the AIBL study. **Mol Psychiatry** 2014; 19: 519-526.
- 14.20 Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, Rentz DM, Johnson KA, Sperling RA, for the Alzheimer's Disease Neuroimaging Initiative, the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing, and the Harvard Aging Brain Study. Amyloid and APOE ϵ 4 interact to influence short-term decline in preclinical Alzheimer disease. **Neurol** 2014; 82: 1760-1767.
- 14.21 Villemagne VL, Fodero-Tavoletti M, Yates P, Masters CL and Rowe CC. A β imaging in aging, Alzheimer's disease and other neurodegenerative conditions. In: *PET and SPECT in Neurology*. Edited by R.A Dierckx, A. Otte, E.F.J. de Vries, A. van Waarde and K.L. Leenders. Berlin Heidelberg: Springer-Verlag; 2014: 213-254.
- 14.22 Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS for the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing: the Alzheimer's Disease Neuroimaging Initiative; and the Alzheimer's Disease Cooperative Study. The preclinical Alzheimer cognitive composite measuring amyloid-related decline. **JAMA Neurol** 2014; 71: 961-970. [See also editorial: Kryscio RJ. Secondary Prevention Trials in Alzheimer Disease: The challenge of identifying a meaningful end point. **JAMA Neurol** 2014; doi10.1001/jamaneurol.2014.1120].
- 14.23 Villemagne VL, Dorè V, Yates P, Brown B, Mulligan R, Bourgeat P, Veljanoski R, Rainey-Smith SR, Ong K, Rembach A, Williams R, Burnham SC, Laws SM, Salvado O, Taddei K, Macaulay SL, Martins RN, Ames D, Masters CL, Rowe CC. En attendant centiloid. **Advances in Research** 2014; 2: 723-729.
- 14.24 Rembach A, Hare DJ, Doecke JD, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR. Decreased serum zinc is an effect of ageing and not Alzheimer's disease. **Metallomics** 2014; 6: 1216-1219.
- 14.25 Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC, Villemagne VL, Macaulay LS, Bush AI, Martins RN, Ames D, Masters CL, Doecke JD and the AIBL research group. An increased Neutrophil-Lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. **J Neuroimmunology** 2014; 273: 65-71.
- 14.26 Brown BM, Bourgeat P, Peiffer JJ, Burnham S, Laws SM, Rainey-Smith SR, Bartrés-Faz D, Villemagne VL, Taddei K, Rembach A, Bush A, Ellis KA, Macaulay SL, Rowe CC, Ames D, Masters CL, Maruff P, Martins RN for the AIBL Research Group. Influence of *BDNF* Val66Met on the relationship between physical activity and brain volume. **Neurology** 2014; 83: 1345-1352.

- 14.27 Buckley RF, Saling MM, Irish M, Ames D, Rowe CC, Villemagne VL, Lautenschlager NT, Maruff P, Macaulay SL, Martins RN, Szoeka C, Masters CL, Rainey-Smith SR, Rembach A, Savage G, Ellis KA and the Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. **Int Psychogeriatrics** 2014; 26:1737-1746.
- 14.28 Johnson P, Vandewater L, Wilson W, Maruff P, Savage G, Graham P, Macaulay SL, Ellis KA, Szoeka C, Martins RN, Rowe CC, Masters CL, Ames D, Zhang P. Genetic algorithm with logistic regression for prediction of progression of Alzheimer's disease. **BMC Bioinformatics** 2014; 15: Suppl 16: S11.
- 14.29 Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M-O, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. **Lancet Neurol** 2014; 13: 614-629.
- 14.30 Okamura N, Furumoto S, Fodero-Tavoletti M, Mulligan R, Harada R, Yates P, Pejoska S, Kudo Y, Masters C, Yanai K, Rowe C, Villemagne V. Noninvasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. **Brain** 2014; 137: 1762-1771.
- 14.31 Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. **Eur J Nucl Med Molec Imag** 2014; 41: 816-826.
- 14.32 Chong TWH, Doyle CJ, Cyarto EV, Cox KL, Ellis KA, Ames D, Lautenschlager N and the AIBL Research Group. Physical activity program preferences and perspectives of older adults with and without cognitive impairment. **Asia Pac Psychiatry** 2014; 6: 179-190.
- 2015**
- 15.01 Gardener SL, Rainey-Smith SR, Barnes MB, Sohrabi HR, Weinborn M, Lim YY, Harrington K, Taddei K, Gu Y, Rembach A, Szoeka C, Ellis KA, Masters CL, Macaulay SL, Rowe CC, Ames D, Keogh JB, Scarmeas N, Martins RN for the AIBL Research Group. Dietary patterns and cognitive decline in an Australian study of ageing. **Molec Psych** 2015; 20: 860-866.
- 15.02 Rembach A, Stingo FC, Peterson C, Vannucci M, Do K-A, Wilson WJ, Macaulay SL, Ryan TM, Martins RN, Ames D, Masters CL, Doecke JD and the AIBL Research Group. Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's Disease. **J Alzheimers Dis** 2015; 44: 917-925.
- 15.03 Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early days and future perspectives. **Lancet Neurol** 2015; 14: 114-124.

- 15.04 Albrecht MA, Szoeka C, Maruff P, Savage G, Lautenschlager N, Ellis K, Taddei K, Martins R, Masters C, Ames D, Foster JK, the AIBL Research Group. Longitudinal cognitive decline in the AIBL cohort: the role of APOE ϵ 4 status. **Neuropsychologia** 2015; 75: 411-419.
- 15.05 Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, Stephens AW, Seibyl J, Dinkelborg LM, Reininger CB, Putz B, Rohde B, Masters CL, Rowe CC. A β imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. **J Neurol Neurosurg Psychiat** 2015; 86: 431-436.
- 15.06 Hollands S, Lim YY, Buckley R, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Lautenschlager N, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P, for the AIBL Research Group. Amyloid- β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. **J Alzheimers Dis** 2015; 43: 677-686.
- 15.07 Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Restrepo C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P for the Australian Imaging, Biomarkers and Lifestyle Research Group. Amyloid- β , anxiety, and cognitive decline in preclinical Alzheimer's disease: A multicentre, prospective cohort study. **JAMA Psychiatry** 2015; 72: 284-291.
- 15.08 Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. **Alzheimers Dement** 2015; 11; 1-15, e1-4.
- 15.09 Watt AD, Perez KA, Ang C-S, O'Donnell P, Rembach A, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Faux NG, Masters CL, Villemagne VL, Barnham KJ. Peripheral α -defensins 1 and 2 are elevated in Alzheimer's disease. **J Alzheimers Dis** 2015; 44: 1131-1143.
- 15.10 Lim YY, Pietrzak RH, Bourgeat P, Ames D, Ellis KA, Rembach A, Harrington K, Salvado O, Martins RN, Snyder PJ, Masters CL, Rowe CC, Villemagne VL, Maruff P. Relationships between performance on the Cogstate Brief Battery, neurodegeneration and A β accumulation in cognitively normal older adults and adults with MCI. **Arch Clin Neuropsych** 2015; 30: 49-58.
- 15.11 Buckley RF, Ellis KA, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Villemagne V, Macaulay SL, Szoeka C, Martins RN, Masters CL, Savage G, Rainey-Smith SR, Rembach A, Saling MM, the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Phenomenological characterisation of memory complaints in preclinical and prodromal Alzheimer's disease. **Neuropsychology** 2015; 29: 571-581.
- 15.12 O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Montine T, Blennow K, Foroud T, Carrillo M, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski J Q, Schupf N, Rissman RA, Fagan A M, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R, for the

STAR-B and BbBIG working groups. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. **Alzheimers Dement** 2015; 11: 549-560.

- 15.13 Laske C, Sohrabi HR, Frost SM, Lopez-de-IPina K, Garrard P, Buscema M, Dauwels J, Soekadar SR, Mueller S, Linnemann C, Bridenbaugh SA, Kanagasingam Y, Martins RN, O'Bryant SE. Innovative diagnostic tools for early detection of Alzheimer's disease. **Alzheimers Dement** 2015; 11: 561-78.
- 15.14 Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, Masters CL, Ames D, Ellis KA, Rowe CC, Salvado O, Fripp J for the AIBL research group. Comparison of MR-less PiB SUVR quantification methods. **Neurobiol of Aging** 2015; 36 Suppl 1: S159-S166.
- 15.15 Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR. Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. **ACS Chem Neurosci** 2015; 6: 398-402.
- 15.16 Gupta VB, Wilson AC, Burnham S, Hone E, Pedrini S, Laws SM, Lim WLF, Rembach A, Rainey-Smith S, Ames D, Cobiac L, Macaulay L, Masters CL, Rowe CC, Bush AI, Martins RN and the AIBL Research Group. Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. **Alzheimers Res Therapy** 2015; 7: 16. Doi: 10.1186/s13195-015-0105-6.
- 15.17 Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton K, Pertile K, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws S, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S for the AIBL Research Group. Alzheimer disease normative CSF biomarkers validated in PET A β characterized subjects from the Australian Imaging, Biomarker and Lifestyle (AIBL) study. **J Alzheimers Dis** 2015; 48: 175-187.
- 15.18 Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Snyder PJ, Martins RN, Masters CL, Rowe CC, Maruff P for the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. *APOE* ϵ 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. **Neurobiology Aging** 2015; 36: 1239-1244.
- 15.19 Merkel B, Steward C, Vivash L, Malpas CB, Phal P, Moffat BA, Cox KL, Ellis KA, Ames D, Cyarto E, Lai MM, Rowe CC, Sharman M, Szoeki C, Masters CL, Lautenschlager NT and Desmond P. Semi-automated hippocampal segmentation in people with cognitive impairments using an age appropriate template for registration. **J Mag Res Imaging**. Doi:10.1002/jmri.24966.
- 15.20 Leifert W, Nguyen T, Rembach A, Martins R, Masters CL, Ames D, Rowe CC, Macaulay SL, François M, Fenech M. Buccal cell cytokeratin 14 correlates with multiple blood biomarkers of Alzheimer's disease risk. **J Alzheimers Dis** 2015; 48: 443-452.

- 15.21 Burnham S, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K, Martins R, Maruff P, Masters C, Romano G, Rowe C, Savage G, Twyman R, Macaulay L, Narayan V, the Alzheimer's Disease Neuroimaging Initiative and the AIBL Research Group. Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal AD trials: An AIBL study. **J Alzheimers Dis** 2015; 46; 1079-1089.
- 15.22 Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P for the AIBL research group. *APOE* and *BDNF* polymorphisms moderate amyloid β -related cognitive decline in preclinical Alzheimer's disease. **Molec Psych** 2015; 20; 1322-1328 [see also: Zakaib GD. Do neutrophin and ApoE together exacerbate Alzheimer's? ALZFORUM (<http://www.alzforum.org/news/research-news/do-neurotrohin-and-apoe-together-exacerbate-alzheimers>). (October 10, 2014).]
- 15.23 Pietrzak RH, Lim YY, Ames D, Harrington K, Restrepo C, Martins RN, Rembach A, Laws SM, Masters CL, Villemagne VL, Rowe CC, Maruff P, for the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. **Neurobiol Aging** 2015; 36; 1231-1238.
- 15.24 Cheng L, Doecke JD, Sharples R, Villemagne VL, Fowler CJ, Rembach A, Martins RN, Rowe C, Macaulay SL, Masters CL, Hill AF, for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. **Molec Psych** 2015; 20: 118-1196.
- 15.25 Dean T & Finkel E. Blood test may be key to Alzheimer's treatment. **Cosmos**. Retrieved from <https://cosmosmagazine.com/life-sciences/blood-test-may-be-key-alzheimer%E2%80%99s-treatment>
- 15.26 Voyle N, Baker D, Burnham SC, Covin A, Zhang Z, Sangurdekar DP, Tan Hehir CA, Bazenet C, Lovestone S, Kiddle S, Dobson RJ. Blood protein markers of neocortical amyloid-beta burden: a candidate study using SOMAscan technology. **J Alzheimers Dis** 2015; 46:947-961.
- 15.27 Hendrix JA, Finger B, Weiner MW, Frisoni GB, Iwatsubo T, Rowe CC, Kim SY, Guinjoan SM, Sevlever G, Carrillo MC. The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. **Alzheimers Dement** 2015; 11:850-859.
- 15.28 Poole SG, Bell JS, Jakanovic N, Kirkpatrick CM, Dooley MJ. A systematic review of medication exposure assessment in prospective cohort studies of community dwelling older australians. **PLoS One** 2015; doi:10.1371/journal.pone.0124247.
- 15.29 Rembach A, Evered LA, Li Q-X, Nash T, Vidaurre L, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Maher S, Mooney F, Farrow M, Taddei K, Rainey-Smith S, Laws SM, Macaulay L, Wilson W, Darby D, Martins R, Ames D, Collins S, Silbert B, Masters CL, Doecke JD and the AIBL Research Group. Alzheimer's disease cerebrospinal fluid

biomarkers are not influenced by gravity drip or aspiration extraction methodology. **Alzheimers Res Ther** 2015; 7: doi:10.1186/s13195-015-0157-7.

- 15.30. Buckley RF, Saling MM, Ellis KA, Rowe CC, Maruff P, Macaulay SL, Martins RN, Masters CL, Savage G, Rainey-Smith SR, Rembach A, Ames D, on behalf of the Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. **Age Ageing** 2015; 44; 1012-1019.
- 15.31. Thai C, Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Ames D, Ellis KA, Rainey-Smith SR, Harrington K, Martins RN, Masters CL, Rowe CC, and Maruff P, for the Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Amyloid-related memory decline in preclinical Alzheimer's disease is dependent on APOE epsilon4 and is detectable over 18-Months. **PLoS One** 2015; 10: e0139082. doi: 10.1371/journal.pone.0139082.
- 15.32 Gardener SL, Rainey-Smith SR, Macaulay SL, Taddei K, Rembach A, Maruff P, Ellis KA, Masters CL, Rowe CC, Ames D, Keogh JB, Martins RN. Comparative analysis of the cancer council of Victoria and the online commonwealth scientific and industrial research organisation FFQ. **Br J Nutr** 2015; 114:1683-1693.
- 15.33 Masters, C. L. (2015, November 8). New prion disease raises questions about whether Alzheimer's and Parkinson's could be infectious. *The Conversation*. Retrieved from <http://theconversation.com/new-prion-disease-raises-questions-about-whether-alzheimers-and-parkinsons-could-be-infectious-46936>

2016

- 16.01 Zwan MD, Villemagne VL, Dore V, Buckley R, Bourgeat P, Veljanoski R, Salvado O, Williams R, Margison L, Rembach A, Macaulay L, Martins R, Ames D, van der Flier WM, Ellis KA, Scheltens P, Masters CL, Rowe CC, for the AIBL study. Subjective memory complaints in *APOE* ϵ 4 carriers are associated with high amyloid- β burden. **J Alzheimers Dis** 2016; 49: 1115-1122.
- 16.02 Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, Maruff P, Salvado O, Ames D, Martins RN, Masters CL, Rowe CC, Villemagne VL for the AIBL Research Group. Clinical and cognitive trajectories in cognitively elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. **Lancet Neurol** 2016; 15: 1044 – 1053. [See also Commentary: Bischof GN. Alzheimer's disease risk: amyloid versus neurodegeneration. **Lancet Neurol** 2016; 15: 1000-1001.
- 16.03 Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BNM, Scheltens P, Barkhof F, Rowe CC, Masters CL, de La Sayette V, Bouwman F, Rabinovici GD. Atrophy, hypometabolism and clinical trajectories in amyloid-negative Alzheimer's disease patients. **Brain** 2016; 139: 2528-2539

- 16.04 Buckley RF, Maruff P, Ames D, Bourgeat P, Martins RN, Masters CL, Rainey-Smith S, Lautenschlager N, Rowe CC, Savage G, Villemagne VL, Ellis KA, and other co-investigators in the AIBL study. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. **Alzheimers Dement** 2016; 12: 796 – 804.
- 16.05 Westwood S, Leoni E, Hye A, Lynham S, Khondoker MR, Ashton NJ, Kiddle SJ, Baird AL, Sainz-Fuertes R, Leung R, Graf J, Hehir CT, Baker D, Cereda C, Bazenet C, Ward M, Thambisetty M, Lovestone S. Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. **J Alzheimers Dis** 2016; 52: 561-72
- 16.06 Gu BJ, Huang X, Ou A, Rembach A, Fowler C, Avula PK, Horton A, Doecke JD, Villemagne VL, Macaulay SL, Maruff P, Fletcher EL, Guymer R, Wiley JS, Masters CL. The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study. Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease. **Acta Neuropath** 2016; 132: 377-389.
- 16.07 Brown BM, Rainey-Smith SR, Villemagne VL, Weinborn M, Bucks RS, Sohrabi HR, Laws SM, Taddei K, Macaulay L, Ames D, Fowler C, Maruff P, Masters CL, Rowe CC, Martins RN, and the AIBL Research Group. The relationship between sleep quality and brain amyloid burden. **Sleep** 2016; 39: 1063-1068.
- 16.08 Lim YY, Snyder PJ, Pietrzak RH, Ukiqi A, Villemagne VL, Ames D, Salvado O, Bourgeat P, Martins RN, Masters CL, Rowe CC, Maruff P for the AIBL Research Group. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. **Alzheimers Dement** 2016; 2: 19-26.
- 16.09 Gupta VB, Doecke JD, Hone E, Pedrini S, Laws SM, Thambisetty M, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Macaulay SL, Rembach A, Rainey-Smith SR, Martins RN and the AIBL Research Group. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging Biomarkers and Lifestyle Study of aging. **Alzheimer Dement (Amst)** 2016; 3: 18-26.
- 16.10 Burnham SC, Rowe CC, Baker D, Bush AI, Doecke JD, Faux NG, Laws SM, Martins RN, Maruff P, Macaulay SL, Rainey-Smith S, Savage G, Ames D, Masters CL, Wilson W, Villemagne VL. Predicting Alzheimer disease from a blood-based biomarker profile: A 54 month follow up. **Neurology** 2016; 87: 1093-1101.
- 16.11 Albrecht MA, Masters CL, Ames D, Foster JK and the AIBL research group. Impact of mild head injury on neuropsychological performance and cognitive decline in cognitively healthy older adults: longitudinal assessment in the AIBL cohort. **Frontiers in Aging Neuroscience** 2016; 8: doi: 10.3389/fnagi.2016.00105.
- 16.12 Baker J, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P. Cognitive impairment and decline in cognitively normal older adults with high amyloid- β : A meta-analysis. **Alzheimers Dement (Amst)** 2016; 18: 108-121.

- 16.13 Yassi N, Desmond PM, Masters CL. Magnetic resonance imaging of vascular contributions to cognitive impairment and dementia. **J Mol Neurosci** 2016; 60: 349-353.
- 16.14 Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Bourgeat P, Martins RN, Salvado O, Rowe CC, Masters CL, Maruff P on behalf of the AIBL research group. Performance on the Cogstate Brief Battery is related to amyloid levels and hippocampal volume in very mild dementia. **J Mol Neurosci** 2016; 60: 362:370.
- 16.15 Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, Sperling R, Amariglio R. A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer's disease. **J Mol Neurosci** 2016; 60: 354-361.
- 16.16 Heffernan AL, Chidgey C, Peng P, Masters CL, Roberts BR. The neurobiology and age-related prevalence of the $\epsilon 4$ allele of apolipoprotein E in Alzheimer's disease cohorts. **J Mol Neurosci** 2016; 60: 316-324.
- 16.17 Harrington KD, Lim YY, Ames D, Hassenstab J, Rainey-Smith S, Robertson J, Salvado O, Masters CL, and Maruff P for the AIBL Research Group. Using robust normative data to investigate the neuropsychology of cognitive aging. **Arch Clin Neuropsych** 2016: 1-13.
- 16.18 Chong TWH, Loi SM, Lautenschlager NT, Ames D. Therapeutic advances and risk factor management: our best chance to tackle dementia? **MJA** 2016; 204: 91-92.
- 16.19 Brown BM, Rainey-Smith SR, Bucks RS, Weinborn M, Martins RN. Exploring the bi-directional relationship between sleep and beta-amyloid. **Curr Opin Psychiatry** 2016; 29: 397-401
- 16.20 François M, Fenech MF, Thomas P, Hor M, Rembach A, Rainey-Smith S, Masters CL, Ames D, Rowe CC, Macaulay SL, The Australian Imaging, Biomarkers and Lifestyle (AIBL) study research group. High content, multi-parameter analyses in buccal cells to identify Alzheimer's disease. **Curr Alzheimer Res** 2016; 13: 787-799
- 16.21 Muenchhoff J, Poljak A, Thalamuthu A, Gupta VB, Chatterjee P, Raftery M, Masters CL, Morris JC, Bateman RJ, Fagan AM, Martins RN, Sachdev PS. Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. **Sci Rep** 2016; 6: doi: 10.1038/srep29078
- 16.22 Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Martins RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, and Maruff P. $A\beta$ -related memory decline in *APOE* $\epsilon 4$ noncarriers: Implications for Alzheimer disease. **Neurology** 2016; 86: 1635-1642
- 16.23 Roberts BR, Doecke JD, Rembach A, Yévenes LF, Fowler CJ, McLean CA, Lind M, Volitakis I, Masters CL, Bush AI, Hare DJ, and the AIBL Research Group. Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid. **Acta Neuropath Comm** 2016; 4: doi: 10.1186/s40478-016-0390-8

2017

- 17.01 Cerin E, Rainey-Smith SR, Ames D, Lautenschlager NT, Macaulay L, Fowler C, Robertson JS, Rowe CC, Maruff P, Martins RN, Masters CL, Ellis KA. Associations of neighbourhood environment with brain imaging outcomes in the AIBL cohort. **Alzheimers Dement** 2017; 13: 388-398.
- 17.02 Gross AL, Hassenstab J, Johnson SC, Clark LR, Resnick SM, Kitner-Triolo M, Masters CL, Maruff P, Morris JC, Soldan A, Pettigrew C, Albert MS. A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: the preclinical AD consortium. **Alzheimers Dement (Amst)** 2017; 8: 147-155
- 17.03 Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S, Salvado O, Bourgeat P, Perez K, Fowler C, Rembach A, Maruff P, Ritchie C, Tanzi R, Masters CL. A randomized exploratory molecular imaging study targeting A β -amyloid with a novel 8-OH quinoline in Alzheimer's disease (The PBT2-204 IMAGINE Study). **Alzheimers Dement (N Y)** 2017; 3: 622-635
- 17.04 Roberts DB, Lind M, Wagen AZ, Rembach A, Frugier TJ, Li Q-X, Ryan TM, McLean CA, Doecke JD, Rowe CC, Villemagne VL, Masters CL. Biochemically-defined pools of amyloid- β in sporadic Alzheimer's disease: correlation with amyloid PET. **Brain** 2017; 140: 1486-1498.
- 17.05 Khan W, Giampietro V, Khondoker M, Faux NG, Ginestet C, Dell'Acqua F, Bouls D, Newhouse S, Dobson R, Banaschewski T, Barker GJ, Bokde ALW, Büchel C, Conrod P, Flor H, Frouin V, Garavan H, Gowland P, Heinz A, Ittermann B, Lamaître H, Nees F, Paus T, Pausova Z, Rietschel M, Smolka MN, Ströhle A, Gallinat J, Vellas B, Soininen H, Kloszewska I, Tsolaki M, Mecocci P, Spenger C, Villemagne VL, Masters CL, Muehlboeck J-S, Wahlund L-O, Schumann G, Lovestone S, Westman E, Simmons A. Alzheimer's Disease Neuroimaging Initiative, AddNeuroMed Consortium, Australian, Imaging, Biomarkers, and Lifestyle Study Research Group, and the IMAGEN consortium. A multi-cohort study of ApoE ϵ 4 and β -amyloid effects on the hippocampus in Alzheimer's disease, mild cognitive impairment and normal ageing. **J Alzheimers Dis** 2017; 56: 1159-1174.
- 17.06 Pietrzak RH, Laws SM, Lim YY, Bender SJ, Porter T, Doecke J, Ames D, Fowler C, Masters CL, Milicic L, Rainey-Smith S, Villemagne VL, Rowe CC, Martins RN, Maruff P for the Australian Imaging, Biomarkers and Lifestyle Research Group. Plasma cortisol, brain amyloid- β , and cognitive decline in preclinical Alzheimer's disease: A 6-year prospective cohort study. **Biol Psychiatry Cogn Neurosci Neuroimaging** 2017; 2: 45-52.
- 17.07 Villemagne VL, Doré V, Bourgeat P, Burnham SC, Laws S, Salvado O, Masters CL and Rowe CC. A β -amyloid and tau imaging in dementia. **Sem Nucl Med** 2017; 47: 75-88.
- 17.08 Frost S, Bhuiyan A, Offerman D, Doecke JD, Macaulay SL, Sohrabi HR, Ames D, Masters CL, Martins RN, Kanagasingham Y and the AIBL Research Group. Modulation of retinal arteriolar central reflection by APOE genotype. **Curr Alzheimer Res** 2017; 14: 916-923

- 17.09 Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, Fowler C, Ellis E, Martins RN, Salvado O, Doré V, Villemagne VL, Rowe CC, Laws SM, Masters CL, Pietrzak RH and Maruff P and for the Australian Imaging, Biomarkers and Lifestyle Research Group. Trajectories of depressive and anxiety symptoms in older adults: A 6-year prospective cohort study. **Int J Geriatr Psych** 2017. doi: 10.1002/gps.4761
- 17.10 Cardoso BR, Hare DJ, Bush AI, Li QX, Fowler CJ, Masters CL, Martins RN, Ganio K, Lothian A, Mukherjee S, Kapp EA, Roberts BR and the AIBL research group. Selenium levels in serum, red blood cells and cerebrospinal fluid of Alzheimer's disease patients: a report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). **J Alzheimers Dis** 2017; 57: 183-193.
- 17.11 Hollands S, Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Harrington K, Porter T, Snyder P, Ames D, Fowler C, Rainey-Smith SR, Martins RN, Salvado O, Robertson J, Rowe CC, Masters CL and Maruff P, for the AIBL research group. *APOE* ϵ 4 genotype, amyloid and clinical disease progression in cognitively normal older adults. **J Alzheimers Dis** 2017; 57: 411-422.
- 17.12 Laws SM, Gaskin S, Woodfield A, Srikanth V, Bruce D, Fraser PE, Porter T, Newsholme P, Wijesekara N, Burnham S, Doré V, Li Q-X, Maruff P, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Villemagne VL, Martins RN, Verdile G. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. **Sci Rep** 2017. 7:9766. doi: 10.1038/541598-017-09577-4
- 17.13 Lim YY, Williamson R, Laws SM, Villemagne VL, Bourgeat P, Fowler C, Rainey-Smith S, Salvado O, Martins RN, Rowe CC, Masters CL, and Maruff P, for the AIBL Research Group. Effect of *APOE* genotype on amyloid deposition, brain volume, and memory in cognitively normal older individuals. **J Alzheimers Dis** 2017; 58:1293-1302
- 17.14 Gardener SL, Rainey-Smith SR, Sohrabi HR, Weinborn M, Verdile G, Fernando WMADB, Lim YY, Harrington K, Burnham S, Taddei K, Masters CL, Macaulay SL, Rowe CC, Ames D, Maruff P, Martins RN, for the AIBL Research Group. Increased carbohydrate intake is associated with poorer performance in verbal memory and attention in an *APOE* genotype- dependent manner. **J Alzheimers Dis** 2017;58:193-201.
- 17.15 Fandos N, Pérez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, Doecke J, Fowler C, Masters CL, Sarasa M and the AIBL Research Group. Plasma amyloid β 42/40 ratios as biomarkers for amyloid- β cerebral deposition in cognitively normal individuals. **Alzheimers Dement (Amst)** 2017; 8; 179-187.
- 17.16 Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY, Diouf I, Farquharson S, Frupp J, Ames D, Doecke J, Desmond P, Ordidge R, Masters CL, Rowe CC, Maruff P, Villemagne VL, the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group, Salvado O, Bush AI. Cerebral quantitative susceptibility mapping predicts amyloid- β -related cognitive decline. **Brain** 2017; 140:2112-2119. [See also Scientific Commentary: Derry PJ, Kent TA. Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer's disease. **Brain** 2017; 140; 2066-2078].

- 17.17 Gupta VB, Hone E, Pedrini S, Doecke J, O'Bryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN and the AIBL Research Group. Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. **Alzheimers Dement (Amst)** 2017; 8: 60-72.
- 17.18 Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Martins RN, Rainey-Smith S, Robertson J, Rowe CC, Salvado O, Doré V, Villemagne VL, Snyder PJ, Masters CL, and Maruff P for the AIBL Research Group. Amyloid- β associated cognitive decline in the absence of clinical disease progression and systemic illness. **Alzheimers Dement (Amst)** 2017; 8: 156–164.
- 17.19 Pedrini S, Gupta VB, Hone E, Doecke J, O'Bryant S, James I, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Martins RN, and the AIBL Research Group. A blood based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β -amyloid load in an AD cohort. **Sci Rep** 2017; 7: 14057. doi: 10.1038/s41598-017-14020-9
- 17.20 Lim YY, Rainey-Smith S, Lim Y, Laws SM, Gupta V, Porter T, Bourgeat P, Ames D, Fowler C, Salvado O, Villemagne VL, Rowe CC, Masters CL, Zhou XF, Martins RN, Maruff P, on the behalf of the AIBL Research Group. *BDNF* Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. **Int Psychogeriatr** 2017 29:1825-1834.
- 17.21 Bourgeat P, Villemagne VL, Dore V, Masters CL, Ames D, Rowe CC, Salvado O, Fripp J, for the AIBL Research Group and for the Alzheimer's Disease Neuroimaging. PET-only ^{18}F -AV1451 tau quantification. (Submitted ISBI conference 2017).
- 17.22 Frost S, Robinson L, Rowe CC, Ames D, Masters CL, Taddei K, Rainey-Smith SR, Martins RN, Kanagasam Y. Evaluation of cholinergic deficiency in preclinical Alzheimer's disease using pupillometry. **J Ophthalmol** 2017; doi.org/10.1155/2017/7935406.
- 17.23 Harrington KD, Gould E, Lim YY, Ames D, Pietrzak RH, Rembach A, Rainey-Smith S, Martins RN, Salvado O, Villemagne VL, Rowe CC, Masters CL and Maruff P for the AIBL Research Group. Amyloid burden and incident depressive symptoms in cognitively normal older adults. **Int J Geriatr Psychiat** 2017; 32: 455-463.
- 17.24 Rangia P, Desmond P, Yates P, Salvado O, Bourgeat P, Fripp J, Pejoska S, Woodward M, Masters CL, Rowe CC, Villemagne VL. Focal $\text{A}\beta$ -amyloid deposition precedes cerebral microbleeds and superficial siderosis: a case report. **J Neurosci Neurol Disord** 2017; 1: 39-44.
- 17.25 Villemagne VL, Doré V, Bougeat P, Burnham S, Mulligan R, Laws S, Fripp J, Cummings T, Salvado O, Masters CL, Rowe CC. The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain. **J Mol Med Ther** 2017; 1: 25-32.

2018

- 18.01 Mito R, Raffelt D, Dhollander T, Vaughan DN, Tournier J-D, Salvado O, Brodtmann B, C Rowe CC, Villemagne VL, Connelly C. Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment. **Brain** 2018; 141: 888–902.
- 18.02 Lan J, Nunez Galindo A, Doecke J, Fowler C, Martins RN, Rainey-Smith SR, Cominetti O, Dayon L. Systematic evaluation of the use of human plasma and serum for mass-spectrometry-based shotgun proteomics. **J Proteome Res** 2018; 17: 1426-1435.
- 18.03 Butcher NJ, Horne MK, Mellick GD, Fowler CJ, Masters CL, AIBL research group and Minchin RF. Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease. **Pharmacogenomics J** 2018; 18: 209-214
- 18.04 Doecke JD, Rembach A, Villemagne VL, Varghese S, Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Taddei K, Laws SM, Macaulay SL, Bush AI, Ellis KA, Martins R, Ames D, Silbert B, Vanderstichele H, Masters CL, Darby DG, Li Q-X, Collins S and the AIBL Research Group. Concordance between cerebrospinal fluid biomarkers with Alzheimer's disease pathology between three independent assay platforms. **J Alzheimers Dis** 2018; 61: 169-183
- 18.05 Porter T, Burnham SC, Doré V, Savage G, Bourgeat P, Begemann K, Milicic L, Ames D, Bush AI, Maruff P, Masters CL, Rowe CC, Rainey-Smith S, Martins RN, Groth D, Verdile G, Villemagne VL, Laws SM. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ϵ 4-positive cognitively normal adults with high A β -amyloid burden. **Sci Rep** 2018; 8: 2034. doi: 10.1038/s41598-018-20513-y.
- 18.06 Lim YY, Kalinowski P, Pietrzak RH, Laws SM, Burnham SC, Ames D, Villemagne VL, Fowler CJ, Rainey-Smith SR, Martins RN, Rowe CC, Masters CL, Maruff PJ. Association of β -amyloid and apolipoprotein E ϵ 4 with memory decline in preclinical Alzheimer disease. **JAMA Neurol** 2018; 75: doi:10.1001/jamaneurol.2017.4325
- 18.07 Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K[enji], Ishii K[anzunari], Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K. High performance plasma amyloid- β biomarkers for Alzheimer's disease. **Nature** 2018; 554: 249-254. [See also Extended Data and Supplementary Information]
- 18.08 Weinborn M, Bucks RS, Sohrabi HR, Rainey-Smith SR, Brown BM, Gardener SL, Gozt A, Christensen D, Savage G, Laws SM, Taddei K, Maruff P, Robertson J, Ellis KA, Ames D, Masters CL, Rowe CC and Martins R for the AIBL research group. Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment and healthy aging: A longitudinal study. **Psychol Assess** 2018; 30: 1308-1316.
- 18.09 Perin S, Harrington KD, Lim YY, Ellis K, Ames D, Pietrzak RH, Schembri A, Rainey-Smith S, Salvado O, Laws SM, Martins RN, Villemagne VL, Rowe CC, Masters CL, Maruff P, for the AIBL research group. Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. **J Affect Disord** 2018; 229: 269-274.

- 18.10 Brown BM, Rainey-Smith SR, Doré V, Peiffer JJ, Burnham SC, Laws SM, Taddei K, Ames D, Masters CL, Rowe CC, Martins RN, Villemagne VL. Self-reported physical activity is associated with tau burden measured by position emission tomography. **J Alzheimers Dis** 2018; 63: 1299-1305.
- 18.11 Fernando WMADB, Rainey-Smith SR, Gardener SL, Villemagne VL, Burnham SC, Macaulay SL, Brown BM, Gupta VB, Sohrabi HR, Weinborn M, Taddei K, Laws SM, Goozee K, Ames D, Fowler C, Maruff P, Masters CL, Salvado O, Rowe CC, Martins RN, for the AIBL Research Group. Associations of dietary protein and fiber intake with brain and blood amyloid- β . **J Alzheimers Dis** 2018; 61: 1589-1598.
- 18.12 Bradfield NI, Ellis KA, Savage G, Maruff P, Burnham S, Darby D, Lautenschlager NT, Martins RN, Masters CL, Rainey-Smith SR, Robertson J, Rowe C, Woodward M and Ames D. Baseline amnesic severity predicts progression from amnesic mild cognitive impairment to Alzheimer disease dementia at 3 years. **Alzheimer Dis Assoc Disord** 2018; 32: 190-196.
- 18.13 Porter T, Burnham SC, Doré V, Savage G, Bourgeat P, Begemann K, Milicic L, Ames D, Bush AI, Maruff P, Masters CL, Rowe CC, Rainey-Smith S, Martins RN, Groth D, Verdile G, Villemagne VL, Laws SM. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ϵ 4-positive cognitively normal adults with high A β -amyloid burden. **Sci Rep** 2018; 8: 2034. doi: 10.1038/s41598-018-20513-y.
- 18.14 Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavado E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkiewicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rütger E, Santana I, Schröder J, Seo SW, Soininen H, Spuru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H1. Association of cerebral amyloid- β aggregation with cognitive functioning in persons without dementia. **JAMA Psychiatry** 2018; 75: 84-95.
- 18.15 Rainey-Smith SR, Mazzucchelli GN, Villemagne VL, Brown BM, Porter T, Weinborn M, Bucks RS, Milicic L, Sohrabi HR, Taddei K, Ames D, Maruff P, Masters CL, Salvado O, Rowe CC, Martins RN, Laws SM, for the AIBL Research Group. Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain A β -amyloid burden. **Trans Psychiat** 2018; 8: 47. doi: 10.1038/s41398-018-0094-x

- 18.16 Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. **Nat Reviews Neurol** 2018; 14: 225-236.
- 18.17 Porter T, Villemagne VL, Savage G, Millicic L, Lim YY, Maruff P, Masters CL, Ames D, Bush AI, Rainey-Smith S, Rowe CC, Groth D, Taddei K, Martins RN, Verdile G, Burnham SC, Laws SM, for the AIBL Research Group. Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. **Personalized Med Psychiatry** 2018; 7: 14-20.
- 18.18 Lan J, Galindo AN, Doecke J, Fowler C, Rainey-Smith SR, Cominetti O, Dayon L. Systematic evaluation of the use of human plasma and serum for mass spectrometry-based shotgun proteomics. **J Proteome Res** 2018; 17: 1426-1435
- 18.19 Doecke JD, Rembach A, Villemagne VL, Varhghese S, Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Taddei K, Laws SM, Macaulay SL, Bush AI, Ellis KA, Martins R, Ames D, Silbert B, Vanderstichele H, Masters CL, Darby DG, Li Q-X, Collins S and the AIBL Research Group. Concordance between cerebrospinal fluid biomarkers with Alzheimer's disease pathology between three independent assay platforms. **J Alzheimers Dis** 2018; 61: 169-183.
- 18.20 Porter T, Burnham SC, Doré V, Savage G, Bourgeat P, Begemann K, Millicic L, Ames D, Bush AI, Maruff P, Masters CL, Rowe CC, Rainey-Smith S, Martins RN, Groth D, Verdile G, Villemagne VL, Laws SM. KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ϵ 4-positive cognitively normal adults with high A β -amyloid burden. **Sci Rep** 2018; 8: 2034. doi: 10.1038/s41598-018-20513-y.
- 18.21 Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, Fowler C, Ellis E, Martins RN, Salvado O, Doré V, Villemagne VL, Rowe CC, Laws SM, Masters CL, Pietrzak RH and Maruff P and for the Australian Imaging, Biomarkers and Lifestyle Research Group. Trajectories of depressive and anxiety symptoms in older adults: A 6-year prospective cohort study. **Int J Geriatr Psychiatry** 2018; 33: 405-413.
- 18.22 Lim YY, Kalinowski P, Pietrzak RH, Laws SM, Burnham SC, Ames D, Villemagne VL, Fowler CJ, Rainey-Smith SR, Martins RN, Rowe CC, Masters CL, Maruff PJ. Association of β -amyloid and apolipoprotein E ϵ 4 with memory decline in preclinical Alzheimer disease. **JAMA Neurol** 2018; 75: 488-494
- 18.23 Weinborn M, Bucks RS, Sohrabi HR, Rainey-Smith SR, Brown BM, Gardener SL, Gozt A, Christensen D, Savage G, Laws SM, Taddei K, Maruff P, Robertson J, Ellis KA, Ames D, Masters CL, Rowe CC and Martins R for the AIBL research group. Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment and healthy aging: A longitudinal study. **Psychol Assess** 2018; 30: 1308-1316.
- 18.24 Perin S, Harrington KD, Lim YY, Ellis K, Ames D, Pietrzak RH, Schembri A, Rainey-Smith S, Salvado O, Laws SM, Martins RN, Villemagne VL, Rowe CC, Masters CL, Maruff P, for the AIBL research group. Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. **J Affect Disord** 2018; 229: 269-274.

- 18.25 Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA, on behalf of Alzheimer's Disease Neuroimaging Initiative, the Australian Imaging Biomarker and Lifestyle study of ageing and the Harvard Aging Brain study. Sex, amyloid and *APOE* ϵ 4 and risk of cognitive decline in preclinical Alzheimer's disease: findings from three well-characterized cohorts. **Alzheimers Dement** 2018; 14: 1193-1203.
- 18.26 Martins RN, Villemagne V, Sohrabi HR, Chatterjee P, Shah TM, Verdile G, Fraser P, Taddei K, Gupta VB, Rainey-Smith SR, Hone I, Pedrini S, Lim WL, Martins I, Frost S, Gupta S, O'Bryant S, Rembach A, Ames D, Ellis K, Fuller SJ, Brown B, Gardener SL, Fernando B, Bharadwaj, P, Burnham S, Laws SM, Barron AM, Goozee K, Wahjoepramono EJ, Asih PR, Doecke JD, Salvado O, Bush AI, Rowe CC, Gandy SE, Masters CL. Alzheimer's disease: A journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies—gains from AIBL and DIAN cohort studies. **J Alzheimers Dis** 2018; 62: 965-992.
- 18.27 Fernando WMADB, Rainey-Smith SR, Gardener SL, Villemagne VL, Burnham SC, Macaulay SL, Brown BM, Gupta VB, Sohrabi HR, Weinborn M, Taddei K, Laws SM, Goozee K, Ames D, Fowler C, Maruff P, Masters CL, Salvado O, Rowe CC, Martins RN, for the AIBL Research Group. Associations of dietary protein and fiber intake with brain and blood amyloid- β . **J Alzheimers Dis** 2018; 61: 1589-1598.
- 18.28 Masters CL, Gu B, Laws S, Ying Lim Y, Roberts B, Villemagne VL, and Beyreuther K. Alzheimer's disease: towards a quantitative biological approach in describing its natural history and underlying mechanisms. In: *The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms*. Edited by Wolfe MS. Cambridge, Massachusetts: Academic Press; 2018: Chapter 3: p. 57-79.
- 18.29 Rainey-Smith SR, Mazzucchelli GN, Villemagne VL, Brown BM, Porter T, Weinborn M, Bucks RS, Milicic L, Sohrabi HR, Taddei K, Ames D, Maruff P, Masters CL, Salvado O, Rowe CC, Martins RN, Laws SM, for the AIBL Research Group. Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain A β -amyloid burden. **Transl Psychiatry** 2018; 8: 47. doi: 10.1038/s41398-018-0094-x
- 18.30 Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. **Nat Reviews Neurol** 2018; 14: 225-236.
- 18.31 Lim YY, Hassenstab J, Goate A, Fagan AM, Benzinger TLS, Cruchaga C, McDade E, Chhatwal J, Levin J, Farlow MR, Graff-Radford NR, Laske C, Masters CL, Salloway S, Schofield P, Morris JC, Maruff P, Bateman RJ, on behalf of the Dominantly Inherited Alzheimer Network. Effect of *BDNF* Val66Met on disease markers in Dominantly Inherited Alzheimers' Disease. **Ann Neurol** 2018; 84: 424-435.
- 18.32 Rainey-Smith S, Gu Y, Gardener SL, Doecke JD, Villemagne VL, Brown BM, Taddei K, Laws SM, Sohrabi HR, Weinborn M, Ames D, Fowler C, Macaulay LS, Maruff P, Masters CL, Salvado O, Rowe CC, Scarmeas N, Martins RN. Mediterranean diet adherence and rate of cerebral A β -amyloid accumulation: data from the Australian

Imaging, Biomarkers and Lifestyle Study of Ageing. **Transl Psychiatry** 2018; 8: 238. doi: 10.1038/s41398-018-0293-5

- 18.33 Bradfield NI, Ellis KA, Savage G, Maruff P, Burnham S, Darby D, Lautenschlager NT, Martins RN, Masters CL, Rainey-Smith SR, Robertson J, Rowe C, Woodward M and Ames D. Baseline amnesic severity predicts progression from amnesic mild cognitive impairment to Alzheimer disease dementia at 3 years. **Alzheimer Dis Assoc Disord** 2018; 32: 190-196.
- 18.34 Baker JE, Lim YY, Jaeger J, Ames D, Lautenschlager NT, Robertson J, Piertrzak R, Snyder P, Villemagne VL, Rowe CC, Masters CL, Maruff P. Episodic memory and learning disfunction over an 18-month period in preclinical and prodromal Alzheimer's disease. **J Alzheimers Dis** 2018; 65: 977-988.
- 18.35 Bourgeat P, Doré V, Fripp J, Ames D, Masters CL, Salvado O, Villemagne VL, Rowe CC, the AIBL Research Group. Implementing the centiloid transformation for ¹¹C-PiB and β -amyloid ¹⁸F-PET tracers using CapAIBL. **Neuro Image** 2018; 183: 387-393
- 18.36 Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM for the AIBL Research Group. Utility of an Alzheimer's disease risk-weighted polygenic risk score for predicting rates of cognitive decline in preclinical Alzheimer's disease: a prospective longitudinal study. **J Alzheimers Dis** 2018; 66: 1193-1211.
- 18.37 Barnier AJ, Harris CB, Morris T, Savage G. Collaborative facilitation in older couples: successful joint remembering across memory tasks. **Front Psychol** 2018; 9: 2385 doi: 10.3389/fpsyg.2018.02385.
- 18.38 Harrington KD, Schembri A, Lim YY, Dang C, Ames D, Hassenstab J, Laws SM, Rainey-Smith S, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P and for the AIBL Research Group. Estimates of age-related memory decline are inflated by unrecognised Alzheimer's disease. **Neurobiol Aging** 2018; 70: 170-179.
- 18.39 Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith SR, Robertson J, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P, for the AIBL Research Group. Relationship between amyloid- β positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults. **J Alzheimers Dis** 2018; 65: 1313-1325.
- 18.40 Müller S, Preische O, Sohrabi H, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C, for the Dominantly Inherited Alzheimer Network (DIAN). Relationship between physical activity, cognition and Alzheimer pathology in autosomal dominant Alzheimer's disease. **Alzheimers Dement** 2018; 14: 1427-1437.

- 18.41 Porter T, Burnham SC, Savage G, Lim YY, Maruff P, Milicic L, Peretti M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Taddei K, Growth D, Verdile G, Villemagne VL, Laws SM. A polygenic risk score derived from episodic memory weighted genetic variants is associated with cognitive decline in preclinical Alzheimer's disease. **Front Aging Neurosci** 2018; 10: 423 doi:10.3389/fnagi.2018.00423.
- 18.42 Dehghani C, Frost S, Jayasena R, Masters CL, Kanagasingam Y. Ocular biomarkers of Alzheimer's disease: the role of anterior eye and potential future directions. **Invest Ophthalmol Vis Sci** 2018; 58: 3554- 3563.
- 18.43 Harrington KD, Dang C, Lim YY, Ames D, Laws SM, Pietrzak RH, Rainey-Smith S, Robertson J, Rowe CC, Salvado O, Villemagne VL, Masters CL, Maruff P for the AIBL Research Group. The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. **Intelligence** 2018; 70: 22-29.

2019

- 19.01 Lothian A, Lago L, Mukherjee S, Fowler C, McLean CA, Horne M, Masters CL, Cappai R, Roberts BR. Characterisation of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn. **Metallomics** 2019; 11: 128- 140.
- 19.02 Taswell C, Donohue C, Mastwyk MT, Louey AG, Giummarra J, Robertson J, Darby DG, Masters CL, Rowe CC. Avoiding methodological bias in studies of amyloid imaging results disclosure. **Alzheimers Res Ther** 2019; doi: 10.1186/s13195-019-0495-y
- 19.03 Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A. A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. **Sci Adv** 2019; 5: eaau7220. doi: 10.1126/sciadv.aau7220.
- 19.04 La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang J-H, Ikonomic MD, Jack C Jr, Jagust WJ, Jin L-W, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD. Multisite study of the relationships between the *antemortem* [¹¹C]PiB-PET Centiloid values and *postmortem* measures of Alzheimer's disease neuropathology. **Alzheimers Dement** 2019; 15: 205-216.
- 19.05 Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, Li QX, Collins SJ, Carlson CM, Asthana S, Masters CL, Johnson S, Morris JC, Abert M, Gross AL. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. **Neurol** 2019; 92: e1567-e1579.
- 19.06 Cox KL, Cyarto EV, Ellis KA, Ames D, Desmond P, Phal P, Sharman MJ, Szeoke C, Rowe CC, Masters CL, You E, Burrows S, Lai MMY, Lautenschlager NT. A

randomized controlled trial of adherence to a 24-month home-based physical activity program and the health benefits for older adults at risk of Alzheimer's disease: The AIBL Active-Study. **J Alzheimers Dis** 2019; 70: S187-S205 doi: 10.3233/JAD-180521.

- 19.07 Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM. Klotho allele status is not associated A β and *APOE* ϵ 4 related cognitive decline in preclinical Alzheimer's disease. **Neurobiol Aging** 2019; 76: 162-165.
- 19.08 Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. **Alzheimers Dement (Amst)** 2019; 11: 180-190.
- 19.09 Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith S, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P, for the AIBL Research Group. Superior memory reduces 8-year risk of mild cognitive impairment and dementia but not amyloid β -associated cognitive decline in older adults. **Arch Clin Neuropsychol** 2019; 34: 585-598.
- 19.10 Bransby L, Lim YY, Ames D, Fowler C, Robertson J, Harrington K, Snyder PJ, Villemagne VL, Salvado O, Masters CL, Maruff P, for the AIBL Research Group. Sensitivity of a preclinical Alzheimer's cognitive composite (PACC) to amyloid β load in preclinical Alzheimer's disease. **J Clin Exp Neuropsychol** 2019; 41: 591-600.
- 19.11 Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Sohrabi HR, Peretti M, Lim YY, Weinborn M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM. *COMT* val158met is not associated with A β -amyloid and *APOE* ϵ 4 related cognitive decline in cognitively normal older adults. **IBRO Rep** 2019; 6: 147-152.
- 19.12 Hata S, Omori C, Kimura A, Saito H, Kimura N, Gupta V, Pedrini S, Hone E, Chatterjee P, Taddei K, Kasuha K, Ikeuchi T, Waragai M, Nishimura M, Hu A, Nakaya T, Meijer L, Maeda M, Yamamoto T, Masters CL, Rowe CC, Ames D, Yamamoto K, Martins RN, Gandy S, Suzuki T. Decrease in p3-Alc β 37 and p3-Alc β 40, products of Alcadein β generated by γ -secretase cleavages, in aged monkeys and patients with Alzheimer's disease. **Alzheimers Dement (N Y)** 2019; 5: 740-750.
- 19.13 Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy J-P, Lesage F, Sylvestre J-P, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume M-A, Beaulieu S, Dirani M, Williamson R, Crowston JG, Nguyen CTO, Bui BV, van Wijngaarden P. Non-invasive, *in vivo* hyperspectral imaging identifies a retinal

biomarker for Alzheimer's disease. **Nat Commun** 2019; 10: 4227 doi: 10.1038/s41467-019-12242-1.

- 19.14 Insel PS, Weiner MW, Mackin RS, Mormino E, Lim YY, Stomrud E, Palmqvist S, Masters CL, Maruff P, Hansson O, Mattsson N for the Alzheimer's Disease Neuroimaging Initiative, the Australian Imaging, Biomarkers, and Lifestyle Study and the Swedish Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Study. Determining clinically meaningful decline in preclinical Alzheimer's disease. **Neurology** 2019; 93: e322-e333.
- 19.15 Shaw LM, Hansson O, Manuilova E, Masters CL, Doeckel JD, Li Q-X, Rutz S, Widmann M, Leinenbach A, Blennow K. Method comparison study of the Elecsys® β -amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. **Clin Biochem** 2019; 72: 7-14.
- 19.16 Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens A, Barthel H, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S. Comparison of ^{18}F -florbetaben quantification results using the standard Centiloid, MR-based and MR-Less CapAIBL® approaches: Validation against histopathology. **Alzheimers Dement** 2019; 15: 807-816.
- 19.17 Xu Y, Li W-W, Wang J, Shen Y-Y, Zeng G-H, Li H-I, Chen D-W, Fowler CI, Li Q-X, Masters CL, Zhou X-F, Wang Y-J. Neurotrophin receptor p75 mRNA levels in the white blood cells of patients with Alzheimer's disease. **Neurotox Res** 2019; 36: 101-107.
- 19.18 Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S, Papp KV, Doré V, Masters CL, Properzo MJ, Schultz AP, Johnson KA, Rentz DM, Sperling RA, Amariglio RE. Using subjective cognitive decline to identify high global amyloid in community-based samples: a cross-cohort study. **Alzheimer Dement (Amst)** 2019; 11: 670-678.
- 19.19 Baker JE, Pietrzak RH, Laws SM, Ames D, Villemagne VL, Rowe CC, Masters CL, Maruff P, Lim YY, on behalf of the AIBL Research Group. Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults. **Neuropsychology** 2019; 33: 964-974.
- 19.20 Huq AJ, Fransquet P, Laws SN, Ryan J, Sebra R, Masters CL, Winship IM, James PA, Lacaze P. Genetic resilience to Alzheimer's disease in APOE ϵ 4 homozygotes: a systematic review. **Alzheimers Dement** 2019; 15: 1612-1623.
- 19.21 Xiong C, Luo J, Agboola S, Li Y, Albert M, Johnson SC, Kosciak RL, Masters CL, Soldan A, Villemagne VL, Li Q-X, McDade EM, Fagan AM, Massoumzadeh P, Benzinger T, Hassenstab J, Bateman RJ, Morris JC, the Dominantly Inherited Alzheimer Network. A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer disease from young adulthood and for designing prevention trials. **Alzheimers Dement** 2019; 15: 1448-1457.
- 19.22 Harris CB, Barnier AJ, Sutton J, Savage G. Features of successful and unsuccessful collaborative memory conversations in long-married couples. **Top Cogn Sci** 2019; 11: 668-686.

- 19.23 Masters CL. [Comment:] Electrode detects A β aggregates in Alzheimer's plasma. <https://www.alzforum.org/news/research-news/electrode-detects-av-aggregates-alzheimers-plasma> (19 April 2019).
- 19.24 Maserejian N, Bian S, Wang W, Jaeger J, Syrjanen JA, Aakre J, Jack CR, Mielke MM, Gao F, for the Alzheimer's Disease Neuroimaging Initiative and the AIBL research team. Practical algorithms for amyloid β probability in subjective or mild cognitive impairment. **Alzheimer Dement (Amst)** 2019; 11: 710-720.
- 19.25 Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K. Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. **Clin Biochem** 2019; 72: 30-38.
- 19.26 Evans S, McRae-McKee K, Hadjichrysanthou C, Wong MM, Ames D, Lopez O, de Wolf F, Anderson RM, for the Alzheimer's disease neuroimaging initiative, the Australian Imaging, Biomarkers and Lifestyle flagship study of ageing, the Predictors of Cognitive Decline Among Normal Individuals (BIOCARD) study, the Add Neuro Med Consortium. Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets. **Alzheimers Dement (N Y)** 2019; 5: 515-523.
- 19.27 Vermunt L, Sikkes SAM, Van den Hout A, Handels R, Bos I, Van der Flier WM, Kern S, Ousset P-J, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin AK, Rikkert MO, Soininen H, Spuru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ, for the Alzheimer Disease Neuroimaging Initiative, AIBL Research Group, ICTUS/DSA study groups. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and *APOE* genotype. **Alzheimers Dement** 2019; 15: 888-898.
- 19.28 Burnham SC, Loi SM, Doecke J, Fedyashov V, Dore V, Villemagne VL, Masters CL. The dawn of robust individualized risk models for dementia. **Lancet Neurol** 2019; 18: 985-987. [Comment on: van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CT, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, R  ther E, Nobili F, Frisoni GB, Spuru L, Freund-Levi Y, Wallin AK, Hampel H, Soininen H, Tsolaki M, Verhey F, K  szewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka S-K, Santana I, Baldeiras I, de Mendon  a A, Silva D, Chetelat G, Egret S, Palmqvist S, Hansson O, Visser PJ, Berkhof J, van der Flier WM for the Alzheimer's Disease Neuroimaging Initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. **Lancet Neurol** 2019; 18: 1034-1044.
- 19.29 Dang C, Yassi N, Harrington KD, Xia Y, Lim YY, Ames D, Laws SM, Hickey M, Rainey-Smith S, Sohrabi HR, Doecke JD, Fripp J, Salvado O, Snyder PJ, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P for the AIBL Research Group. Rates of age- or amyloid β -associated cortical atrophy in older adults with superior memory performance. **Alzheimers Dement (Amst)** 2019; 11: 566 – 575.

- 19.30 Vacher M, Porter T, Villemagne VL, Milicic L, Peretti M, Fowler C, Martins R, Rainey-Smith S, Ames D, Masters CL, Rowe CC, Doecke JD, Laws SM. Validation of *a priori* candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. **Sci Rep** 2019; 9: 17069 doi: 10.1038/s41598-019-53604-5.
- 19.31 Burnham SC, Coloma PM, Li Q-X, Collins S, Savage G, Laws S, Doecke J, Maurff P, Martina RN, Ames D, Rowe CC, Masters CL, Villemagne VL. Application of the NIA-AA Research Framework: Towards a biological definition of Alzheimer's disease using cerebrospinal fluid biomarkers in the AIBL study. **J Prev Alzheimers Dis** 2019; 6: 248-255.
- 19.32 Franzmeier N, Ren J, Damm A, Monté-Runio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodriguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin K, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Gran S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee J-H, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MA, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M. The *BDNF^{Val66Met}* SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. **Molec Psych** 2019; doi: 10.1038/s41380-019-0404-6.

2020

- 20.01 Lai MMY, Sharman MJ, Ames DJ, Ellis KA, Cox KL, Hepworth G, Desmond P, Cyarto EV, Martins RN, Masters CL, Lautenschlager NT. Relationship of established cardiovascular risk factors and peripheral biomarkers on cognitive function in adults at risk of cognitive deterioration. **J Alzheimers Dis** 2020; 74: 163-171.
- 20.02 Eratne D, Loi SM, Walia N, Farrand S, Li Q-X, Varghese S, Walterfang M, Evans A, Mocellin R, Dhiman K, Gupta V, Malpas CB, Collins S, Masters CL, Velakoulis D. A. Pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: a "C-reactive protein" for psychiatrists and neurologists? **Aust N Z J Psychiatry** 2020; 54: 57-67.
- 20.03 Yassi N, Hilal S, Xia Y, Lim YY, Watson R, Kuijf H, Fowler C, Yates P, Maruff P, Martins R, Ames D, Chen C, Rowe CC, Villemagne VL, Salvado O, Desmond PM, Masters CL. Influence of comorbidity of cerebrovascular disease and amyloid- β on Alzheimer's disease. **J Alzheimers Dis** 2020; 73: 897-907.
- 20.04 Amadoru S, Doré V, McLean CA, Hinton F, Shepherd CE, Halliday GM, Leyton CE, Yates PA, Hodges JR, Masters CL, Villemagne VL, Rowe CC. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. **Alzheimers Res Ther** 2020; 12: 22 doi: 10.1186/s13195-020-00587-5.
- 20.05 Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Dore V, Fripp J, Ames D, Masters CL, Rowe CC, Connelly A, Villemagne VL, Salvado O, for the Australian

Imaging Biomarkers and Lifestyle (AIBL) Research Group. Increased cerebral blood flow with increased amyloid burden in the preclinical phase of Alzheimer's disease. **J Magn Reson Imaging** 2020; 51: 505-513.

- 20.06 Baker JE, Bruns L, Hassenstab J, Masters CL, Maruff P, Lim YY. Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults. **J Clin Exp Neuropsychol** 2020; 42: 55-65.
- 20.07 Pomponio R, Erus G, Habes M, Doshi J, Srinivasan D, Mamourian E, Bashyam V, Nasrallah IM, Satterthwaite TD, Fan Y, Launer LJ, Masters CL, Maruff P, Zhou C, , Völzke H, Johnson SC, Fripp J, Koutsouleris N, Wolf DH, Gur R[aque], Gur R[uben], Morris J, Albert MS, Grabe HJ, Resnick SM, Bryan RN, Wolk DA, Shinohara RT, Shou H, Davatzikos C. Harmonization of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan. **Neuroimage** 2020; 208: 116450.
- 20.08 Bashyam VM, Erus G, Doshi J, Habes M, Nasrallah I, Truelove-Hill M, Srinivasan D, Mamourian L, Pomponio R, Fan Y, Launer LJ, Masters CL, Maruff P, Zhou C, Völzke H, Johnson SC, Fripp J, Koutsouleris N, Satterthwaite TD, Wolf D, Gur RE, Gur RC, Morris J, Albert MS, Grabe HJ, Resnick S, Bryan RN, Wolk DA, Shou H, Davatzikos C. MRI signatures of brain age and disease over lifespan based on a Deep Brain Network and 14,468 people worldwide. **Brain** 2020; 143: 2312-2324.
- 20.09 Klatt S, Roberts AM, Lothian A, Masters CL, Cappai R, Fowler CJ, Roberts BR. Optimising red blood cell protein extraction for biomarker quantitation with mass spectrometry. **Anal Bioanal Chem** 2020, 412: 1879-1892.
- 20.10 Lai MMY, Ames DJ, Cox KL, Ellis KA, Sharman MJ, Hepworth G, Desmond P, Cyarto EV, Szoek C, Martins R, Masters CL, Lautenschlager NT. Association between cognitive function and clustered cardiovascular risk of metabolic syndrome in older adults at risk of cognitive decline. **J Nutr Health Aging** 2020; 24: 300-304.
- 20.11 Doecke JD, Pérez-Grijalba V, Fandos N, Fowler C, Villemagne VL, Masters CL, Pesini P, Sarasa M, for the AIBL Research Group. Total A β 42/A β 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. **Neurology** 2020; 94: e1580-e1591 doi 10.1212/WNL.00000000000009240.
- 20.12 Papp KV, Buckley R, Mormino E, Maruff P, Villemagne VL, Masters CL, Johnson KA, Rentz DM, Sperling RA, Amariglio RE, on behalf of Collaborators from the Harvard Aging Brain Study, the Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging, Biomarker and Lifestyle study of Aging. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. **Alzheimers Dement** 2020; 16: 552-560
- 20.13 Dhiman K, Gupta VB, Villemagne VL, Eratne D, Graham PL, Fowler C, Bourgeat P, Li Q-X, Collins S, Bush AI, Rowe CC, Masters CL, Ames D, Hone E, Blennow K, Zetterberg H, Martins RN. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. **Alzheimers Dement (Amst)** 2020; 12: e12005 doi: 10.1002/dad2.12005.

- 20.14 Doecke JD, Ward L, Burnham SC, Villemagne VL, Li Q-X, Collins S, Fowler CJ, Manuilova E, Widmann M, Rainey-Smith SR, Martins RN, Masters CL and the AIBL Research Group. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. **Alzheimers Res Ther** 2020; 12: 36 doi: 10.1186/s13195-020-00595-5.
- 20.15 Venkatraman VK, Steward CE, Cox KL, Ellis KA, Phal PM, Sharman MJ, Villemagne VL, Lai MMY, Cyarto EV, Ames D, Szoeka C, Rowe CC, Masters CL, Lautenschlager NT, Desmond PM. Baseline white matter is associated with physical fitness change in preclinical Alzheimer's disease. **Front Aging Neurosci.** 2020; 12: 115 doi: 10.3389/fnagi.2020.00115. eCollection 2020.
- 20.16 Fazlollahi A, Raniga P, Bourgeat P, Yates P, Bush AI, Salvado O, Ayton S. Restricted effect of cerebral microbleeds on regional magnetic susceptibility. **J Alzheimers Dis** 2020; 76: 571-577.
- 20.17 Schindler SE, Jicha GA, Nelson PT, Keene CD, Blennow K, Molinuevo JL, Masters CL, Hansson O, Teunissen CE, Galasko D, Shaw LM, Levey AI. Maximising safety in the conduct of Alzheimer's disease fluid biomarker research in the era of COVID-19. **J Alzheimers Dis** 2020; 76: 27-31.
- 20.18 Dehghani C, Frost S, Jayasena R, Fowler C, Masters CL, Kanagasigam Y, Jiao H, Lim JKH, Chinnery HR, Downie LE. Morphometric changes to corneal dendritic cells in individuals with mild cognitive impairment (MCI). **Frontiers Neuroscience** 2020; 14: 556137 doi10.3389/fnins.2020.556137.
- 20.19 Burnham SC, Fandos N, Fowler C, Pérez-Grijalba V, Dore V, Doecke JD, Shishegar R, Cox T, Fripp J, Rowe C, Sarasa M, Masters CL, Pesini P, Villemagne VL. Longitudinal evaluation of the natural history of amyloid- β in plasma and brain. **Brain Comm** 2020; 2: fcaa041 doi: 10.1093/braincomms/fcaa041.
- 20.20 Masters CL. [Comment] Major risk factors for Alzheimer's disease: age and genetics. **Lancet Neurol** 2020; 19: 475-476
- 20.21 Venkatraman VK, Sanderson A, Cox KL, Ellis KA, Steward C, Phal PM, Gorelik A, Sharman MJ, Villemagne VL, Lai M, Cyarto EV, Merkel B, Ames D, Szoeka C, Rowe CC, Masters CL, Lautenschlager NT, Desmond PM. Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. **Neurobiol Aging** 2020; 89: 132-141.
- 20.22 Peterson CB, Osborne N, Stingo FC, Bourgeat P, Doecke JD, Vannucci M. Bayesian modeling of multiple structural connectivity networks during the progression of Alzheimer's disease. **Biometrics** 2020; 76: 1120-1132.
- 20.23 Van Havre Z, Maruff P, Villemagne VL, Mengersen K, Rousseau J, White N, Doecke JD. Identification of pre-clinical Alzheimer's Disease in a population of elderly cognitively normal participants. **J Alzheimers Dis** 2020; 73: 683-693.
- 20.24 Lim YY, Baker JE, Bruns L, Mills A, Fowler C, Fripp J, Rainey-Smith SR, Ames D, Masters CL, Maruff P. Association of deficits in short-term learning and A β

and hippocampal volume in cognitively normal adults. **Neurology** 2020; 95: e2577-e2585 [See also commentary: In preclinical Alzheimer's, learning falters before memory, *Alzforum* 18 Sept 2020 <https://www.alzforum.org/news/research-news/preclinical-alzheimers-learning-falters-memory>]

- 20.25 Habes M, Pomponio R, Shou H, Doshi J, Mamourian L, Erus G, Nasrallah I, Launer LJ, Rashid T, Bilgel M, Fan Y, Toledo JB, Yaffe K, Sotiras A, Srinivasan D, Espeland M, Masters C[L], Maruff P, Fripp J, Völzk H, Johnson SC, Morris JC, Albert MS, Miller MI, Bryan RN, Grabe HJ, Resnick SM, Wolk DA, Davatzikos C for the iSTAGING consortium, the Preclinical AD consortium, the ADNI, and the CARDIA studies. The Brain Chart of Aging: Machine-learning analytics reveal links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. **Alz Dem** 2020; doi: 10.1002/alz.12178.
- 20.26 Wu HZY, Thalamuthu A, Cheng L, Fowler C, Masters CL, Sachdev P, Mather KA and the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. Differential blood miRNA expression in brain amyloid imaging defined Alzheimer's disease and controls. **Alzheimers Res Ther** 2020; 12: 59 doi: 10.1186/s13195-020-00627-0.
- 20.27 Cheng L, Vella LJ, Barnham KJ, McLean C, Masters CL, Hill AD. Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles.. **J Extracell Vesicles** 2020; 9: 1766822 doi: 10.1080/20013078.2020.1766822.
- 20.28 Ashraf A, Ashton NJ, Chatterjee P, Goozee K, Shen K, Fripp J, Ames D, Rowe C, Masters CL, Villemagne V, Hye A, Martins RN, So P-W and AIBL. Plasma transferrin and haemopexin are associated with altered A β uptake and cognitive decline in Alzheimer's disease pathology. **Alzheimers Res Ther** 2020; 12: 72. doi: 10.1186/s13195-020-00634-1.
- 20.29 Lim B, Fowler C, Li Q-X, Rowe C, Dhiman K, Gupta VB, Masters CL, Doecke JD, Martins RN, Collins S, Diamandis EP. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-A β load and cerebrospinal fluid A β in a pilot study of Alzheimer's study. **Neurosci Lett** 2020; 731: 135078.
- 20.30 Pedrini S, Hone E, Gupta VB, James I, Teimouri E, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Rainey-Smith S, Verdile G, Sohrabi HR, Raida MR, Wenk MR, Taddei K, Chatterjee P, Martins I, Laws SM, Martins RN and the AIBL Research Group. Plasma high density lipoprotein small subclass is reduced in Alzheimer's disease patients and correlates with cognitive performance. **J Alz Dis** 2020; 77: 733-744.
- 20.31 Siddiqui MS, Francois M, Rainey-Smith S, Martins R, Masters CL, Ames D, Rowe CC, Macaulay LS, Fenech MF, Leifert WR. Evaluation of GammaH2AX in buccal cells as a molecular biomarker of DNA damage in Alzheimer's Disease in the AIBL study of ageing. **Life (Basel)** 2020; 10: e141 doi: 10.3390/life10080141.
- 20.32 Xia Y, Yassi N, Raniga P, Bourgeat P, Desmond P, Doecke J, Ames D, Laws SM, Fowler C, Rainey-Smith SR, Martins R, Maruff P, Villemagne VL, Masters CL, Rowe CC, Fripp J, Salvado O for the AIBL Research Group. Comorbidity of cerebrovascular and Alzheimer's disease in aging. **J Alz Dis** 2020; 78: 321-334.

- 20.33 Burnham SC, Laws SM, Budgeon CA, Doré V, Porter T, Bourgeat P, Buckley RF, Murray K, Ellis KA, Turlack BA, Salvado O, Ames D, Martins RN, Rentz D, Masters CL, Rowe CC, Villemagne VL, for the Alzheimer's Disease Neuroimaging Initiative, and the AIBL Research Group. Impact of APOE- ϵ 4 carriage on the onset and rates of neocortical A β -amyloid deposition. **Neurobiol Aging** 2020; 95: 46-55.
- 20.34 Bradfield NI, Ellis KA, Savage G, Maruff P, Burnham S, Darby D, Lautenschlager NT, Martins RN, Masters CL, Rainey-Smith SR, Robertson J, Rowe C, Woodward M, Ames D. Aggregation of abnormal memory scores and risk of incident Alzheimer disease dementia: a measure of objective memory impairment in Mild Cognitive Impairment. **J Int Neuropsychol Soc** 2020; 1-2 doi: 10.1017/S135561772000079X.
- 20.35 Huynh K, Lim WLF, Giles C, Jayawardana KS, Salim A, Mellett NA, Smith A, Olshansky G, Drew BG, Chatterjee P, Martins I, Laws SM, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Arnold M, Nho K, Saykin AJ, Baillie R, Han X, Kaddurah-Daouk R, Martins RN, Meikle PJ. Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. **Nature Comms** 2020; 11: 5698.
- 20.36 Baker JE, Bruns L, Hassenstab J, Masters CL, Maruff P, Lim YY. Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults. **J Clin Exp Neuropsychol** 2020; 42: 55-65.
- 20.37 Lim YY, Maruff P, Kaneko N, Doecke J, Fowler C, Villemagne VL, Kato T, Rowe CC, Arahata Y, Iwamoto S, Ito K, Tanaka K, Yanagisawa K, Masters CL, Nakamura A. Plasma amyloid- β biomarker associated with cognitive decline in preclinical Alzheimer's disease. **J Alz Dis** 2020; 77: 1057-1065.
- 20.38 Lim WLF, Huynh K, Chatterjee P, Martins I, Jayawardana KS, Giles C, Mellett NA, Laws SM, Bush AI, Rowe CC, Villemagne VL, Ames D, Drew BG, Masters CL, Meikle PJ, Martins RN, AIBL Research Group. Relationships between plasma lipids, species, gender, risk factors and Alzheimer's disease. **J Alzheimers Dis** 2020; 76: 303-315.
- 2021**
- 21.01 Liu Y-H, Wang J, Li Q-X, Fowler CJ, Zeng F, Deng J, Xu Z-Q, Zhou H-D, Doecke JD, Villemagne VL, Lim YY, Masters CL, Wang Y-J. Association of naturally occurring antibodies to β -amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. **Sci Advances** 2021; 7: eabb0457
- 21.02 van der Kall LM, Truong T, Burnham SC, Doré V, Mulligan RS, Bozinovski S, Lamb F, Bourgeat P, Fripp J, Schultz S, Lim YY, Laws SM, Ames D, Fowler C, Rainey-Smith SR, Martins RN, Salvado O, Robertson J, Maruff P, Masters CL, Villemagne VL and Rowe CC. Association of β -Amyloid level, clinical progression and longitudinal cognitive change in normal older individuals. **Neurology** 2021; 96: 1-9 doi: 10.1212/WNL.00000000000011222.

- 21.03 Lim YY, Laws SM, Perin S, Pietrzak RH, Fowler C, Masters CL, Maruff P, on behalf of the AIBL Research Group. BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease. **Genes Brain Behav** In Press (December 2020).
- 21.04 Groot C, Doré V, Robertson J, Burnham S, Savage G, Ossenkoppele R, Rowe CC, Villemagne VL. Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in β -amyloid negative cognitively normal individuals. **Neurobiol Aging** 2021; 97: 41-48.
- 21.05 Fowler C, Rainey-Smith SR, Bird S, Bomke J, Bourgeat P, Brown BM, Burnham SC, Bush AI, Chadunow C, Collins S, Doecke J, Doré V, Ellis KA, Evered L, Fazlollahi A, Fripp J, Gardener SL, Gibson S, Grenfell R, Harrison E, Head R, Jin L, Kamer A, Lamb F, Lautenschlager NT, Laws SM, Li QX, Lim L, Lim YY, Louey A, Macaulay SL, Mackintosh L, Martins RN, Maruff P, Masters CL, McBride S, Milicic L, Peretti M, Pertile K, Porter T, Radler M, Rembach A, Robertson J, Rodrigues M, Rowe CC, Rumble R, Salvado O, Savage G, Silbert B, Soh M, Sohrabi HR, Taddei K, Taddei T, Thai C, Trounson B, Tyrrell R, Vacher M, Villemagne VL, Weinborn M, Woodward M, Xia Y, Ames D, and the AIBL investigators. A decade of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study: Progress and observations from 2500 participants spanning the spectrum from cognitive health to Alzheimer's disease. Manuscript submitted (December 2020).
- 21.06 Lim YY, Baker JE, Mills A, Bruns L, Fowler C, Fripp J, Rainey-Smith SR, Ames D, Masters CL, Maruff P. Learning deficit in cognitively normal APOE ϵ 4 carriers with low β -amyloid. **Alzheimers Dement (Amst)** 2021; 13: e12136.
- 21.07 Nik SHM, Porter T, Newman M, Bartlett B, Khan I, Sabale M, Eccles M, Groth D, Doré V, Villemagne V, Masters CL, Martins R, Laws S, Lardelli M, Verdile G. Relevance of truncated PRESENILIN 2 transcript to Alzheimer's disease and neurodegeneration. **J Alz Dis** 2021; 80: 1479-1489.
- 21.08 Bourgeat P, Doré V, Doecke J, Ames D, Masters CL, Rowe CC, Fripp J, Villemagne VL and the AIBL research group. Non-negative matrix factorization improves Centiloid robustness in longitudinal studies. **Neuroimage** 2021; 226: 117593.